Diabetes Mellitus, Type 2
Conditions
Keywords
GLP-1,, Type 2 Diabetes,, pharmacokinetics,, pharmacodynamics,, GSK716155,, metformin,, exenatide, Type 2 Diabetes Mellitus
Brief summary
This study is a placebo-controlled study in patients with Type 2 Diabetes Mellitus who are either taking no diabetes medication or who are taking metformin only. This study will investigate the safety, tolerability, and efficacy of Albiglutide (GSK716155) and will measure the levels of Albiglutide (GSK716155) in the bloodstream when it is given for 16 weeks. As a comparison, some subjects will receive exenatide instead of Albiglutide (GSK716155). The study will involve weekly visits for 17 weeks,and less frequent follow-up visits for an additional 10 weeks. Assessments include repeat blood sampling and monitoring of any side effects.
Detailed description
A 16-week, parallel-group, double-blind, randomized, placebo-controlled, multicenter, dose-ranging study to evaluate the efficacy, safety and tolerability of multiple doses and multiple treatment regimens of Albiglutide (GSK716155) with Byetta as an open-label active reference, in subjects with Type 2 Diabetes Mellitus.
Interventions
DRUGAlbiglutide (GSK716155) or exenatide
Albiglutide weekly subcutaneous injection or exenatide twice daily injection
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Has type 2 diabetes mellitus as defined by the criteria of the American Diabetes Association and recognized by World Health Organization Expert Committee on the Diagnosis and Classification of Diabetes Mellitus \[American Diabetes Association, 2004a\] at least three months preceding screening * Has concurrent type 2 diabetes mellitus therapy: Must be diet and exercise treated; must not have taken antidiabetic medication for at least three months prior to prescreening or Monotherapy with metformin, with a history of a stable dose for at least three months before prescreening (not taking more than one oral antidiabetic agent) * Has HbA1c level at screening ≥7 and ≤10% * Is male or female 18 to 75 years of age, inclusive, at screening * Has body mass index ≥20 and ≤40 kg/m² * If subject is a smoker, must be able to abstain while in clinic at each visit * If female, is eligible to enter and participate throughout the study, including the follow-up period: 1) If of nonchildbearing potential (i.e. physiologically incapable of becoming pregnant {tubal ligation}, including any female who is postmenopausal \[\>1 year without menstrual period\]); or, 2) If of childbearing potential, has negative pregnancy tests at screening (serum) and at baseline (urine) and: 3) Has a male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject, or 4) Uses double-barrier methods of contraception; condoms (with spermicide) and intrauterine devices are acceptable, or 5) Uses hormonal contraceptives (oral, depots, patches, etc) with double-barrier methods of contraception as outlined above, or, 6) Abstains from sexual intercourse, or 7) Is with a same-sex partner and does not participate in bisexual activities where there is any risk of pregnancy * Signs and dates informed consent before any study-related procedures are performed
Exclusion criteria
* Has metabolic disease including but not limited to: 1) Diagnosis of type 1 diabetes mellitus, 2) Uncorrected thyroid dysfunction (NOTE: subjects with hypothyroidism on a stable dose of thyroid replacement therapy for at least three months prior to screening, and who have a screening thyroid-stimulating hormone within the limits of normal may participate) * Has qualitative changes in lifestyle that, in the opinion of the investigator, would affect the subject's weight or disease status * Had previous use of insulin within one month prior to screening, or more than seven total days of insulin treatment within three months prior to screening * Has clinically significant cardiovascular and/or cerebrovascular disease including, but not limited to: 1) Previous history of stroke or transient ischemic attack, 2) Active, unstable coronary heart disease within the past six months, 3) Documented myocardial infarction within a year prior to screening 4) Any cardiac surgery including percutaneous transluminal coronary angioplasty or coronary artery bypass graft surgery within a year prior to screening 5) Unstable angina 6) Clinically significant arrhythmia or valvular heart disease within the past year 7) Congestive heart failure with New York Heart Association Class II to Class IV symptoms. Class I is acceptable. 8) Untreated hypertension, with systolic pressure greater than 160mm Hg and/or diastolic pressure greater than 95mm Hg. 9) ECG
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 | Baseline and Week 16 | HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline in HbA1c was calculated as the value at Week 16 minus the value at Baseline. Based on ANCOVA: Change = treatment + Baseline HbA1c + prior therapy + gender + region. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Weeks (W) 4, 5, 7, 8, 9, 12, 15, and 16 | The number of participants who achieved target values for HbA1c (i.e., HbA1c \<6.5% and \>=6.5% to \<7%) were assessed. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. |
| Change From Baseline in Waist Circumference at Week 16 | Baseline and Week 16 | The Baseline value is the last non-missing value before the start of treatment. Change from Baseline in waist circumference was calculated as the value at Week 16 minus the value at Baseline. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. |
| Change From Baseline in Body Weight at Week 16 | Baseline and Week 16 | The Baseline value is the last non-missing value before the start of treatment. Change from Baseline in body weight was calculated as the value at Week 16 minus the value at Baseline. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. |
| Percent Change From Baseline in Body Weight at Week 16 | Baseline and Week 16 | The Baseline value is the last non-missing value before the start of treatment. Change from Baseline in body weight was calculated as the value at Week 16 minus the value at Baseline. Percent change from Baseline was calculated as the (\[value at Week 16 minus the Baseline value\] divided by the Baseline value) multiplied by 100. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Baseline and Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | The FPG test measures blood sugar levels after the participant has not eaten (fasted) for at least eight hours prior to the sampling. The Baseline FPG value is the last non-missing value before the start of treatment. Change from Baseline in FPG was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. |
| Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Baseline and Weeks 5, 8, 12, and 16 | Fasting fructosamine levels were measured after the participant had not eaten (fasted) for at least eight hours prior to the sampling. The Baseline fructosamine value is the last non-missing value before the start of treatment. Change from Baseline in fructosamine was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. |
| Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Baseline and Weeks 5, 8, 12, and 16 | Fasting C-peptide levels were measured after the participant had not eaten (fasted) for at least eight hours prior to the sampling. The Baseline C-peptide value is the last non-missing value before the start of treatment. Change from Baseline in C-peptide was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. |
| Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Baseline and Weeks 5, 8, 12, and 16 | Fasting glucagon levels were measured after the participant had not eaten (fasted) for at least eight hours prior to the sampling. The Baseline glucagon value is the last non-missing value before the start of treatment. Change from Baseline in glucagon was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. |
| Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Baseline and Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline in HbA1c was calculated as the post-Baseline value minus the value at Baseline. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. |
| Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Baseline and Weeks 5, 8, 12, and 16 | Serum lipid components, including triglycerides (TG), free fatty acids (FFA), total cholesterol (CL), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), were measured at Baseline and Weeks 5, 8, 12, and 16. The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. |
| Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | Baseline and Week 16 | The FLIE questionnaire is used to record the participant's feelings/opinions concerning the effects of nausea/vomiting on their quality of life during the past five days. Participants completed the questionnaire by responding to 18 questions. The first set of 9 questions refer to nausea, and the second set of 9 questions refer to vomiting. Each question is scored on a seven-point visual analog scale (1 to 7). On this scale, a score of 1 corresponds to 0 millimeters (mm), and a score of 7 correspond to 100 mm. Anything in between is marked at the appropriate point on the scale and is measured in mm. Data are reported in mm in this table. In FLIE questions (FLIEQ) 1, 2, 4, 5, 7, 8, 9, 10, 12, 13, 14, 16, and 17, a score of 1 indicates no effect on the quality of life, and a score of 7 indicates a great effect on the quality of life. In FLIEQ 3, 6, 11, 15, and 18, a score of 1 indicates a great effect on the quality of life, and a score of 7 indicates no effect on the quality of life. |
| Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Week 16 | The HCFQ questionnaire is used to record how often participants have felt hungry or craved food, and how full participants felt after finishing meals, on average, in the past week. Participants answered the following seven questions with the response that best described their feelings of hunger, craving, and fullness: Q1, In the past week I was hungry; Q2, In the past week I thought about food; Q3, In the past week I wanted to eat; Q4, In the past week I ate more than I should have; Q5, In the past week, I craved specific food; Q6, In the past week when finished meals I felt full; Q7, In the past week when finished meals I felt satisfied. |
| Mean Clearance of Albiglutide | Weeks 0, 4, 5, 7, 8, 9, 12, 15, 16, 17 18, 20, 23, and 27 | Clearance is defined as the volume of plasma cleared of albiglutide per unit time. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 4, 5, 7, 8, 9, 12, 15) and on the day of the clinic visit at Weeks 16, 17, 18, 20, 23, and 27. The Week 5, 8, and 12 post-dose pharmacokinetic (PK) sampling was performed within 6 days of drug administration. |
| Mean Volume of Distribution of Albiglutide | Weeks 0, 4, 5, 7, 8, 9, 12, 15, 16, 17 18, 20, 23, and 27 | Volume of distribution is defined as the apparent volume in which albiglutide is distributed. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 4, 5, 7, 8, 9, 12, 15) and on the day of the clinic visit at Weeks 16, 17, 18, 20, 23, and 27. The Week 5, 8, and 12 post-dose (PK sampling was performed within 6 days of drug administration. |
| Mean Absorption Rate of Albiglutide | Weeks 0, 4, 5, 7, 8, 9, 12, 15, 16, 17 18, 20, 23, and 27 | Absorption rate is defined as the rate at which albiglutide enters the blood circulation. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 4, 5, 7, 8, 9, 12, 15) and on the day of the clinic visit at Weeks 16, 17, 18, 20, 23, and 27. The Week 5, 8, and 12 post-dose (PK sampling was performed within 6 days of drug administration. |
| Mean Half-maximal Effective Concentration (EC50) of Albiglutide for HbA1c and FPG | Weeks 0, 4, 5, 7, 8, 9, 12, 15, 16, 17 18, 20, 23, and 27 | EC50 is defined as the concentration of albiglutide that give a half-maximal HbA1c and FPG response. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 4, 5, 7, 8, 9, 12, 15) and on the day of the clinic visit at Weeks 16, 17, 18, 20, 23, and 27. The Week 5, 8, and 12 post-dose (PK sampling was performed within 6 days of drug administration. EC50 estimates used PK data as well as HbA1c and FPG efficacy data. EC50 was estimated from an inhibitory Emax (maximal possible effect of albiglutide) model. |
| Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Baseline and Weeks 5, 8, 12, and 16 | Fasting insulin levels were measured after the participant had not eaten (fasted) for at least eight hours prior to the sampling. The Baseline insulin value is the last non-missing value before the start of treatment. Change from Baseline in insulin was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. |
Countries
Chile, Dominican Republic, United States
Participant flow
Pre-assignment details
A total of 361 participants were randomized into the study; however, only 356 of these participants received at least one dose of study drug.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Participants received placebo weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body. | 51 |
| Exenatide BID Participants self-administered exenatide as a subcutaneous injection using prefilled pens, in accordance with current prescribing information. A dose of 5 micrograms (μg) was administered twice daily (BID) for the first 4 weeks, followed by a 12-week administration of a 10 μg BID dose. Participants who could not tolerate a 10 μg dose were to continue the study on the 5 μg BID dose. | 35 |
| Albiglutide 4 mg Weekly Participants received albiglutide 4 milligrams (mg) weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body. | 35 |
| Albiglutide 15 mg Weekly Participants received albiglutide 15 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body. | 35 |
| Albiglutide 30 mg Weekly Participants received albiglutide 30 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body. | 31 |
| Albiglutide 15 mg Bi-weekly Participants received albiglutide 15 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body. | 33 |
| Albiglutide 30 mg Bi-weekly Participants received albiglutide 30 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body. | 32 |
| Albiglutide 50 mg Bi-weekly Participants received albiglutide 50 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body. | 35 |
| Albiglutide 50 mg Every 4 Weeks Participants received albiglutide 50 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body. | 35 |
| Albiglutide 100 mg Every 4 Weeks Participants received albiglutide 100 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body. | 34 |
| Total | 356 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 6 | 1 | 5 | 6 | 5 | 5 | 5 | 10 | 2 | 9 |
| Overall Study | Different Monotherapy Diabetic Drug | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Overall Study | Family Emergency; Had to Go to England | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Lack of Efficacy | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Overall Study | Lost to Follow-up | 0 | 0 | 2 | 3 | 1 | 3 | 0 | 1 | 1 | 1 |
| Overall Study | Moved Out of State | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Overall Study | Non-Compliance | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 |
| Overall Study | Physician Prescribed Antidiabetic Drug | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Protocol Violation | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Treatment Eligibility Criteria Not Met | 1 | 1 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 |
| Overall Study | Violation of Exclusion Criteria | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 1 | 1 | 5 | 0 | 2 | 1 | 0 | 2 | 1 | 3 |
| Overall Study | Withdrew Consent | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Overall Study | Wrong Monotherapy Administered | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Placebo | Exenatide BID | Albiglutide 4 mg Weekly | Albiglutide 15 mg Weekly | Albiglutide 30 mg Weekly | Albiglutide 15 mg Bi-weekly | Albiglutide 30 mg Bi-weekly | Albiglutide 50 mg Bi-weekly | Albiglutide 50 mg Every 4 Weeks | Albiglutide 100 mg Every 4 Weeks | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 54.0 Years STANDARD_DEVIATION 10.62 | 53.7 Years STANDARD_DEVIATION 9.38 | 50.4 Years STANDARD_DEVIATION 10.25 | 55.5 Years STANDARD_DEVIATION 10.48 | 54.2 Years STANDARD_DEVIATION 9.66 | 52.5 Years STANDARD_DEVIATION 9.55 | 55.5 Years STANDARD_DEVIATION 9.87 | 51.1 Years STANDARD_DEVIATION 10.25 | 54.1 Years STANDARD_DEVIATION 11.3 | 54.4 Years STANDARD_DEVIATION 9.89 | 53.5 Years STANDARD_DEVIATION 10.17 |
| Gender Female | 23 Participants | 19 Participants | 20 Participants | 17 Participants | 23 Participants | 19 Participants | 16 Participants | 16 Participants | 18 Participants | 15 Participants | 186 Participants |
| Gender Male | 28 Participants | 16 Participants | 15 Participants | 18 Participants | 8 Participants | 14 Participants | 16 Participants | 19 Participants | 17 Participants | 19 Participants | 170 Participants |
| Race/Ethnicity, Customized African American/African Heritage | 8 Participants | 10 Participants | 7 Participants | 4 Participants | 3 Participants | 3 Participants | 5 Participants | 4 Participants | 6 Participants | 5 Participants | 55 Participants |
| Race/Ethnicity, Customized American Indian or Alaskan Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 0 Participants | 5 Participants |
| Race/Ethnicity, Customized Asian - Central/South Asian Heritage | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 4 Participants | 1 Participants | 1 Participants | 1 Participants | 9 Participants |
| Race/Ethnicity, Customized Asian - East Asian Heritage | 2 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 0 Participants | 8 Participants |
| Race/Ethnicity, Customized Asian - Japanese Heritage | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Asian - South East Asian Heritage | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 2 Participants | 0 Participants | 1 Participants | 5 Participants |
| Race/Ethnicity, Customized Hispanic | 3 Participants | 0 Participants | 4 Participants | 7 Participants | 2 Participants | 3 Participants | 5 Participants | 5 Participants | 4 Participants | 4 Participants | 37 Participants |
| Race/Ethnicity, Customized Hispanic, Puerto Rican | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Mestizo | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized Mexican | 3 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 2 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 8 Participants |
| Race/Ethnicity, Customized Mulatto | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 3 Participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 1 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 5 Participants |
| Race/Ethnicity, Customized Puerto Rican | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized White- Arabic/North African Heritage | 4 Participants | 2 Participants | 2 Participants | 4 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 3 Participants | 0 Participants | 17 Participants |
| Race/Ethnicity, Customized White - White/Caucasian/European Heritage | 29 Participants | 20 Participants | 18 Participants | 19 Participants | 20 Participants | 21 Participants | 14 Participants | 19 Participants | 18 Participants | 20 Participants | 198 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 29 / 51 | 22 / 35 | 24 / 35 | 20 / 35 | 22 / 31 | 22 / 33 | 25 / 32 | 27 / 35 | 27 / 35 | 26 / 34 |
| serious Total, serious adverse events | 2 / 51 | 1 / 35 | 0 / 35 | 3 / 35 | 7 / 31 | 2 / 33 | 5 / 32 | 5 / 35 | 7 / 35 | 5 / 34 |
Outcome results
Primary
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline in HbA1c was calculated as the value at Week 16 minus the value at Baseline. Based on ANCOVA: Change = treatment + Baseline HbA1c + prior therapy + gender + region. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Time frame: Baseline and Week 16
Population: Intent-to-Treat (ITT) Population: all randomly assigned participants with at least one post-Baseline assessment of the primary endpoint. Participants from the exenatide arm were not included in the analysis. Only those participants with a value at Baseline and at the specified visit were analyzed.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 | -0.46 Percentage of HbA1c in the blood | Standard Error 0.136 |
| Albiglutide 4 mg Weekly | Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 | -0.25 Percentage of HbA1c in the blood | Standard Error 0.159 |
| Albiglutide 15 mg Weekly | Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 | -0.71 Percentage of HbA1c in the blood | Standard Error 0.16 |
| Albiglutide 30 mg Weekly | Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 | -1.08 Percentage of HbA1c in the blood | Standard Error 0.175 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 | -0.68 Percentage of HbA1c in the blood | Standard Error 0.167 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 | -1.01 Percentage of HbA1c in the blood | Standard Error 0.162 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 | -1.03 Percentage of HbA1c in the blood | Standard Error 0.159 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 | -0.80 Percentage of HbA1c in the blood | Standard Error 0.157 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 | -1.06 Percentage of HbA1c in the blood | Standard Error 0.161 |
p-value: 0.296895% CI: [-0.18, 0.59]ANCOVA
p-value: 0.18695% CI: [-0.64, 0.12]ANCOVA
p-value: 0.002795% CI: [-1.03, -0.22]ANCOVA
p-value: 0.276695% CI: [-0.62, 0.18]ANCOVA
p-value: 0.005795% CI: [-0.94, -0.16]ANCOVA
p-value: 0.003295% CI: [-0.96, -0.19]ANCOVA
p-value: 0.078695% CI: [-0.72, 0.04]ANCOVA
p-value: 0.002295% CI: [-0.99, -0.22]ANCOVA
Secondary
Change From Baseline in Body Weight at Week 16
The Baseline value is the last non-missing value before the start of treatment. Change from Baseline in body weight was calculated as the value at Week 16 minus the value at Baseline. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Time frame: Baseline and Week 16
Population: ITT Population. Only participants with a value at Baseline and at Week 16 were analyzed.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Body Weight at Week 16 | -0.71 Kilograms (Kg) | Standard Deviation 2.883 |
| Exenatide BID | Change From Baseline in Body Weight at Week 16 | -2.41 Kilograms (Kg) | Standard Deviation 3.527 |
| Albiglutide 4 mg Weekly | Change From Baseline in Body Weight at Week 16 | -0.91 Kilograms (Kg) | Standard Deviation 1.733 |
| Albiglutide 15 mg Weekly | Change From Baseline in Body Weight at Week 16 | -0.90 Kilograms (Kg) | Standard Deviation 2.901 |
| Albiglutide 30 mg Weekly | Change From Baseline in Body Weight at Week 16 | -1.43 Kilograms (Kg) | Standard Deviation 2.371 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Body Weight at Week 16 | -1.76 Kilograms (Kg) | Standard Deviation 2.828 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Body Weight at Week 16 | -1.59 Kilograms (Kg) | Standard Deviation 2.455 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Body Weight at Week 16 | -1.14 Kilograms (Kg) | Standard Deviation 2.872 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Body Weight at Week 16 | -1.08 Kilograms (Kg) | Standard Deviation 3.177 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Body Weight at Week 16 | -1.65 Kilograms (Kg) | Standard Deviation 3.57 |
Secondary
Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16
Fasting C-peptide levels were measured after the participant had not eaten (fasted) for at least eight hours prior to the sampling. The Baseline C-peptide value is the last non-missing value before the start of treatment. Change from Baseline in C-peptide was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Time frame: Baseline and Weeks 5, 8, 12, and 16
Population: ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 5, n=48,33,32,33,27,28,32,33,35,30 | 0.004 Nanomoles per liter (nmol/L) | Standard Deviation 0.4464 |
| Placebo | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,33,34,28,29,32,33,35,31 | -0.019 Nanomoles per liter (nmol/L) | Standard Deviation 0.4044 |
| Placebo | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,33,34,28,29,32,33,35,33 | -0.092 Nanomoles per liter (nmol/L) | Standard Deviation 0.4264 |
| Placebo | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,33,34,28,29,32,33,35,33 | -0.091 Nanomoles per liter (nmol/L) | Standard Deviation 0.3149 |
| Exenatide BID | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,33,34,28,29,32,33,35,31 | 0.104 Nanomoles per liter (nmol/L) | Standard Deviation 0.4643 |
| Exenatide BID | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 5, n=48,33,32,33,27,28,32,33,35,30 | 0.274 Nanomoles per liter (nmol/L) | Standard Deviation 0.7431 |
| Exenatide BID | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,33,34,28,29,32,33,35,33 | 0.216 Nanomoles per liter (nmol/L) | Standard Deviation 0.6786 |
| Exenatide BID | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,33,34,28,29,32,33,35,33 | 0.174 Nanomoles per liter (nmol/L) | Standard Deviation 0.5445 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,33,34,28,29,32,33,35,31 | -0.073 Nanomoles per liter (nmol/L) | Standard Deviation 0.2813 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 5, n=48,33,32,33,27,28,32,33,35,30 | -0.020 Nanomoles per liter (nmol/L) | Standard Deviation 0.3374 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,33,34,28,29,32,33,35,33 | -0.044 Nanomoles per liter (nmol/L) | Standard Deviation 0.3426 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,33,34,28,29,32,33,35,33 | -0.051 Nanomoles per liter (nmol/L) | Standard Deviation 0.3877 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 5, n=48,33,32,33,27,28,32,33,35,30 | -0.034 Nanomoles per liter (nmol/L) | Standard Deviation 0.6149 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,33,34,28,29,32,33,35,31 | -0.026 Nanomoles per liter (nmol/L) | Standard Deviation 0.6237 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,33,34,28,29,32,33,35,33 | -0.046 Nanomoles per liter (nmol/L) | Standard Deviation 0.5904 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,33,34,28,29,32,33,35,33 | -0.075 Nanomoles per liter (nmol/L) | Standard Deviation 0.6046 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,33,34,28,29,32,33,35,33 | 0.023 Nanomoles per liter (nmol/L) | Standard Deviation 0.3698 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,33,34,28,29,32,33,35,31 | 0.095 Nanomoles per liter (nmol/L) | Standard Deviation 0.552 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,33,34,28,29,32,33,35,33 | 0.171 Nanomoles per liter (nmol/L) | Standard Deviation 0.44 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 5, n=48,33,32,33,27,28,32,33,35,30 | 0.089 Nanomoles per liter (nmol/L) | Standard Deviation 0.3459 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,33,34,28,29,32,33,35,33 | -0.098 Nanomoles per liter (nmol/L) | Standard Deviation 0.3773 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,33,34,28,29,32,33,35,31 | -0.038 Nanomoles per liter (nmol/L) | Standard Deviation 0.3931 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 5, n=48,33,32,33,27,28,32,33,35,30 | 0.015 Nanomoles per liter (nmol/L) | Standard Deviation 0.3782 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,33,34,28,29,32,33,35,33 | -0.059 Nanomoles per liter (nmol/L) | Standard Deviation 0.401 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,33,34,28,29,32,33,35,31 | -0.015 Nanomoles per liter (nmol/L) | Standard Deviation 0.7842 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,33,34,28,29,32,33,35,33 | -0.153 Nanomoles per liter (nmol/L) | Standard Deviation 0.6463 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,33,34,28,29,32,33,35,33 | -0.137 Nanomoles per liter (nmol/L) | Standard Deviation 0.654 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 5, n=48,33,32,33,27,28,32,33,35,30 | -0.128 Nanomoles per liter (nmol/L) | Standard Deviation 0.699 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 5, n=48,33,32,33,27,28,32,33,35,30 | 0.004 Nanomoles per liter (nmol/L) | Standard Deviation 0.413 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,33,34,28,29,32,33,35,33 | -0.066 Nanomoles per liter (nmol/L) | Standard Deviation 0.4025 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,33,34,28,29,32,33,35,31 | -0.062 Nanomoles per liter (nmol/L) | Standard Deviation 0.3735 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,33,34,28,29,32,33,35,33 | -0.076 Nanomoles per liter (nmol/L) | Standard Deviation 0.4458 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,33,34,28,29,32,33,35,33 | 0.076 Nanomoles per liter (nmol/L) | Standard Deviation 0.5365 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 5, n=48,33,32,33,27,28,32,33,35,30 | 0.072 Nanomoles per liter (nmol/L) | Standard Deviation 0.413 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,33,34,28,29,32,33,35,33 | 0.155 Nanomoles per liter (nmol/L) | Standard Deviation 0.5257 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,33,34,28,29,32,33,35,31 | 0.031 Nanomoles per liter (nmol/L) | Standard Deviation 0.4738 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,33,34,28,29,32,33,35,33 | 0.062 Nanomoles per liter (nmol/L) | Standard Deviation 0.6038 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 5, n=48,33,32,33,27,28,32,33,35,30 | 0.230 Nanomoles per liter (nmol/L) | Standard Deviation 0.3595 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,33,34,28,29,32,33,35,33 | -0.005 Nanomoles per liter (nmol/L) | Standard Deviation 0.4312 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,33,34,28,29,32,33,35,31 | 0.007 Nanomoles per liter (nmol/L) | Standard Deviation 0.3363 |
Secondary
Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16
Fasting fructosamine levels were measured after the participant had not eaten (fasted) for at least eight hours prior to the sampling. The Baseline fructosamine value is the last non-missing value before the start of treatment. Change from Baseline in fructosamine was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Time frame: Baseline and Weeks 5, 8, 12, and 16
Population: ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 5, n=48,34,32,33,28,29,32,34,35,29 | -8.3 Micromoles per liter (µmol/L) | Standard Deviation 38.68 |
| Placebo | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,33,34,28,29,32,34,35,31 | -10.1 Micromoles per liter (µmol/L) | Standard Deviation 41.37 |
| Placebo | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,33,34,28,29,32,34,35,33 | -11.2 Micromoles per liter (µmol/L) | Standard Deviation 41.61 |
| Placebo | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,33,34,28,29,32,34,35,33 | -3.2 Micromoles per liter (µmol/L) | Standard Deviation 46.33 |
| Exenatide BID | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,33,34,28,29,32,34,35,31 | -30.6 Micromoles per liter (µmol/L) | Standard Deviation 32.47 |
| Exenatide BID | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 5, n=48,34,32,33,28,29,32,34,35,29 | -24.7 Micromoles per liter (µmol/L) | Standard Deviation 38.65 |
| Exenatide BID | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,33,34,28,29,32,34,35,33 | -24.6 Micromoles per liter (µmol/L) | Standard Deviation 41.88 |
| Exenatide BID | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,33,34,28,29,32,34,35,33 | -30.1 Micromoles per liter (µmol/L) | Standard Deviation 35.78 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,33,34,28,29,32,34,35,31 | -13.1 Micromoles per liter (µmol/L) | Standard Deviation 50.64 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 5, n=48,34,32,33,28,29,32,34,35,29 | -11.9 Micromoles per liter (µmol/L) | Standard Deviation 50.55 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,33,34,28,29,32,34,35,33 | -12.5 Micromoles per liter (µmol/L) | Standard Deviation 55.41 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,33,34,28,29,32,34,35,33 | -7.8 Micromoles per liter (µmol/L) | Standard Deviation 56.38 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 5, n=48,34,32,33,28,29,32,34,35,29 | -23.8 Micromoles per liter (µmol/L) | Standard Deviation 20.74 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,33,34,28,29,32,34,35,31 | -25.7 Micromoles per liter (µmol/L) | Standard Deviation 31.34 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,33,34,28,29,32,34,35,33 | -26.7 Micromoles per liter (µmol/L) | Standard Deviation 30.61 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,33,34,28,29,32,34,35,33 | -18.2 Micromoles per liter (µmol/L) | Standard Deviation 28.01 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,33,34,28,29,32,34,35,33 | -31.8 Micromoles per liter (µmol/L) | Standard Deviation 35.07 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,33,34,28,29,32,34,35,31 | -35.5 Micromoles per liter (µmol/L) | Standard Deviation 26.97 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,33,34,28,29,32,34,35,33 | -30.8 Micromoles per liter (µmol/L) | Standard Deviation 31.05 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 5, n=48,34,32,33,28,29,32,34,35,29 | -30.7 Micromoles per liter (µmol/L) | Standard Deviation 31.28 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,33,34,28,29,32,34,35,33 | -25.2 Micromoles per liter (µmol/L) | Standard Deviation 46.21 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,33,34,28,29,32,34,35,31 | -28.9 Micromoles per liter (µmol/L) | Standard Deviation 42.46 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 5, n=48,34,32,33,28,29,32,34,35,29 | -21.3 Micromoles per liter (µmol/L) | Standard Deviation 36.67 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,33,34,28,29,32,34,35,33 | -23.0 Micromoles per liter (µmol/L) | Standard Deviation 49.58 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,33,34,28,29,32,34,35,31 | -40.9 Micromoles per liter (µmol/L) | Standard Deviation 43.73 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,33,34,28,29,32,34,35,33 | -40.2 Micromoles per liter (µmol/L) | Standard Deviation 43.37 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,33,34,28,29,32,34,35,33 | -38.1 Micromoles per liter (µmol/L) | Standard Deviation 43.17 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 5, n=48,34,32,33,28,29,32,34,35,29 | -34.4 Micromoles per liter (µmol/L) | Standard Deviation 41.71 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 5, n=48,34,32,33,28,29,32,34,35,29 | -30.1 Micromoles per liter (µmol/L) | Standard Deviation 41.75 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,33,34,28,29,32,34,35,33 | -29.4 Micromoles per liter (µmol/L) | Standard Deviation 56.23 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,33,34,28,29,32,34,35,31 | -32.7 Micromoles per liter (µmol/L) | Standard Deviation 42.44 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,33,34,28,29,32,34,35,33 | -32.7 Micromoles per liter (µmol/L) | Standard Deviation 48.01 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,33,34,28,29,32,34,35,33 | -26.5 Micromoles per liter (µmol/L) | Standard Deviation 40.27 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 5, n=48,34,32,33,28,29,32,34,35,29 | -29.2 Micromoles per liter (µmol/L) | Standard Deviation 46.57 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,33,34,28,29,32,34,35,33 | -26.4 Micromoles per liter (µmol/L) | Standard Deviation 46.85 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,33,34,28,29,32,34,35,31 | -24.9 Micromoles per liter (µmol/L) | Standard Deviation 40.03 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,33,34,28,29,32,34,35,33 | -31.1 Micromoles per liter (µmol/L) | Standard Deviation 52.14 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 5, n=48,34,32,33,28,29,32,34,35,29 | -32.5 Micromoles per liter (µmol/L) | Standard Deviation 32.4 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,33,34,28,29,32,34,35,33 | -24.9 Micromoles per liter (µmol/L) | Standard Deviation 49.08 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,33,34,28,29,32,34,35,31 | -29.5 Micromoles per liter (µmol/L) | Standard Deviation 49.98 |
Secondary
Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16
Fasting glucagon levels were measured after the participant had not eaten (fasted) for at least eight hours prior to the sampling. The Baseline glucagon value is the last non-missing value before the start of treatment. Change from Baseline in glucagon was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Time frame: Baseline and Weeks 5, 8, 12, and 16
Population: ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 5, n=48,33,33,33,27,28,32,34,35,30 | 3.8 Nanograms per liter (ng/L) | Standard Deviation 43.63 |
| Placebo | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,34,34,28,29,32,34,35,31 | 6.9 Nanograms per liter (ng/L) | Standard Deviation 49.05 |
| Placebo | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,34,34,28,29,32,34,35,33 | 0.1 Nanograms per liter (ng/L) | Standard Deviation 49.48 |
| Placebo | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,34,34,28,29,32,34,35,33 | -2.1 Nanograms per liter (ng/L) | Standard Deviation 45.73 |
| Exenatide BID | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,34,34,28,29,32,34,35,31 | -14.8 Nanograms per liter (ng/L) | Standard Deviation 38.34 |
| Exenatide BID | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 5, n=48,33,33,33,27,28,32,34,35,30 | -3.9 Nanograms per liter (ng/L) | Standard Deviation 39.26 |
| Exenatide BID | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,34,34,28,29,32,34,35,33 | -4.5 Nanograms per liter (ng/L) | Standard Deviation 41.1 |
| Exenatide BID | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,34,34,28,29,32,34,35,33 | -5.5 Nanograms per liter (ng/L) | Standard Deviation 32.41 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,34,34,28,29,32,34,35,31 | -5.6 Nanograms per liter (ng/L) | Standard Deviation 22.91 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 5, n=48,33,33,33,27,28,32,34,35,30 | -3.2 Nanograms per liter (ng/L) | Standard Deviation 27.16 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,34,34,28,29,32,34,35,33 | -8.6 Nanograms per liter (ng/L) | Standard Deviation 31.51 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,34,34,28,29,32,34,35,33 | -3.9 Nanograms per liter (ng/L) | Standard Deviation 26.72 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 5, n=48,33,33,33,27,28,32,34,35,30 | -13.9 Nanograms per liter (ng/L) | Standard Deviation 29.05 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,34,34,28,29,32,34,35,31 | -15.6 Nanograms per liter (ng/L) | Standard Deviation 32.75 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,34,34,28,29,32,34,35,33 | -20.1 Nanograms per liter (ng/L) | Standard Deviation 36.53 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,34,34,28,29,32,34,35,33 | -20.5 Nanograms per liter (ng/L) | Standard Deviation 36.06 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,34,34,28,29,32,34,35,33 | -4.5 Nanograms per liter (ng/L) | Standard Deviation 21.6 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,34,34,28,29,32,34,35,31 | -2.4 Nanograms per liter (ng/L) | Standard Deviation 17.78 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,34,34,28,29,32,34,35,33 | -2.6 Nanograms per liter (ng/L) | Standard Deviation 22.7 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 5, n=48,33,33,33,27,28,32,34,35,30 | -3.6 Nanograms per liter (ng/L) | Standard Deviation 21.95 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,34,34,28,29,32,34,35,33 | -11.1 Nanograms per liter (ng/L) | Standard Deviation 39.08 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,34,34,28,29,32,34,35,31 | -12.4 Nanograms per liter (ng/L) | Standard Deviation 32.17 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 5, n=48,33,33,33,27,28,32,34,35,30 | -6.0 Nanograms per liter (ng/L) | Standard Deviation 26.83 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,34,34,28,29,32,34,35,33 | -7.1 Nanograms per liter (ng/L) | Standard Deviation 32.75 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,34,34,28,29,32,34,35,31 | -3.1 Nanograms per liter (ng/L) | Standard Deviation 22.64 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,34,34,28,29,32,34,35,33 | 0.2 Nanograms per liter (ng/L) | Standard Deviation 24.55 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,34,34,28,29,32,34,35,33 | -5.0 Nanograms per liter (ng/L) | Standard Deviation 17.95 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 5, n=48,33,33,33,27,28,32,34,35,30 | -7.6 Nanograms per liter (ng/L) | Standard Deviation 20.72 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 5, n=48,33,33,33,27,28,32,34,35,30 | -11.6 Nanograms per liter (ng/L) | Standard Deviation 29.48 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,34,34,28,29,32,34,35,33 | -10.9 Nanograms per liter (ng/L) | Standard Deviation 34.41 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,34,34,28,29,32,34,35,31 | -10.7 Nanograms per liter (ng/L) | Standard Deviation 34.48 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,34,34,28,29,32,34,35,33 | -3.3 Nanograms per liter (ng/L) | Standard Deviation 35.85 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,34,34,28,29,32,34,35,33 | -11.5 Nanograms per liter (ng/L) | Standard Deviation 25.21 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 5, n=48,33,33,33,27,28,32,34,35,30 | -9.3 Nanograms per liter (ng/L) | Standard Deviation 23.21 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,34,34,28,29,32,34,35,33 | -3.7 Nanograms per liter (ng/L) | Standard Deviation 38.02 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,34,34,28,29,32,34,35,31 | -0.3 Nanograms per liter (ng/L) | Standard Deviation 41.71 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 12, n=50,34,34,34,28,29,32,34,35,33 | -2.1 Nanograms per liter (ng/L) | Standard Deviation 23.58 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 5, n=48,33,33,33,27,28,32,34,35,30 | 1.9 Nanograms per liter (ng/L) | Standard Deviation 30.27 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 16, n=50,34,34,34,28,29,32,34,35,33 | -4.7 Nanograms per liter (ng/L) | Standard Deviation 18.59 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16 | Week 8, n=50,34,34,34,28,29,32,34,35,31 | 0.5 Nanograms per liter (ng/L) | Standard Deviation 27.94 |
Secondary
Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16
Fasting insulin levels were measured after the participant had not eaten (fasted) for at least eight hours prior to the sampling. The Baseline insulin value is the last non-missing value before the start of treatment. Change from Baseline in insulin was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Time frame: Baseline and Weeks 5, 8, 12, and 16
Population: ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 5, n=47,31,32,33,27,28,31,30,33,30 | 5.1 Picomoles per liter (pmol/L) | Standard Deviation 106.67 |
| Placebo | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 16, n=49,32,33,34,28,29,32,31,33,33 | -5.8 Picomoles per liter (pmol/L) | Standard Deviation 42.74 |
| Placebo | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 12, n=49,32,33,34,28,29,32,31,33,33 | 8.8 Picomoles per liter (pmol/L) | Standard Deviation 79.93 |
| Placebo | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 8, n=49,32,33,34,28,29,32,31,33,31 | 9.2 Picomoles per liter (pmol/L) | Standard Deviation 106.05 |
| Exenatide BID | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 5, n=47,31,32,33,27,28,31,30,33,30 | 29.6 Picomoles per liter (pmol/L) | Standard Deviation 104.29 |
| Exenatide BID | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 12, n=49,32,33,34,28,29,32,31,33,33 | 18.0 Picomoles per liter (pmol/L) | Standard Deviation 60.31 |
| Exenatide BID | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 16, n=49,32,33,34,28,29,32,31,33,33 | 17.4 Picomoles per liter (pmol/L) | Standard Deviation 52.62 |
| Exenatide BID | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 8, n=49,32,33,34,28,29,32,31,33,31 | 5.4 Picomoles per liter (pmol/L) | Standard Deviation 52.47 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 16, n=49,32,33,34,28,29,32,31,33,33 | 2.9 Picomoles per liter (pmol/L) | Standard Deviation 81.64 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 5, n=47,31,32,33,27,28,31,30,33,30 | -12.4 Picomoles per liter (pmol/L) | Standard Deviation 72.9 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 12, n=49,32,33,34,28,29,32,31,33,33 | -12.4 Picomoles per liter (pmol/L) | Standard Deviation 67.03 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 8, n=49,32,33,34,28,29,32,31,33,31 | -16.5 Picomoles per liter (pmol/L) | Standard Deviation 64.88 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 16, n=49,32,33,34,28,29,32,31,33,33 | -19.9 Picomoles per liter (pmol/L) | Standard Deviation 112.32 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 8, n=49,32,33,34,28,29,32,31,33,31 | -8.5 Picomoles per liter (pmol/L) | Standard Deviation 116.41 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 12, n=49,32,33,34,28,29,32,31,33,33 | -7.9 Picomoles per liter (pmol/L) | Standard Deviation 106.19 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 5, n=47,31,32,33,27,28,31,30,33,30 | -16.4 Picomoles per liter (pmol/L) | Standard Deviation 114.61 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 5, n=47,31,32,33,27,28,31,30,33,30 | 0.4 Picomoles per liter (pmol/L) | Standard Deviation 75.97 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 16, n=49,32,33,34,28,29,32,31,33,33 | 25.1 Picomoles per liter (pmol/L) | Standard Deviation 114.95 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 12, n=49,32,33,34,28,29,32,31,33,33 | -1.1 Picomoles per liter (pmol/L) | Standard Deviation 86.02 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 8, n=49,32,33,34,28,29,32,31,33,31 | 2.4 Picomoles per liter (pmol/L) | Standard Deviation 98.07 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 5, n=47,31,32,33,27,28,31,30,33,30 | 28.5 Picomoles per liter (pmol/L) | Standard Deviation 99.26 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 16, n=49,32,33,34,28,29,32,31,33,33 | 21.9 Picomoles per liter (pmol/L) | Standard Deviation 99.41 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 12, n=49,32,33,34,28,29,32,31,33,33 | 17.8 Picomoles per liter (pmol/L) | Standard Deviation 99.18 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 8, n=49,32,33,34,28,29,32,31,33,31 | 18.6 Picomoles per liter (pmol/L) | Standard Deviation 102.92 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 16, n=49,32,33,34,28,29,32,31,33,33 | -24.0 Picomoles per liter (pmol/L) | Standard Deviation 90.05 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 5, n=47,31,32,33,27,28,31,30,33,30 | -38.3 Picomoles per liter (pmol/L) | Standard Deviation 104.22 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 12, n=49,32,33,34,28,29,32,31,33,33 | -26.1 Picomoles per liter (pmol/L) | Standard Deviation 94.1 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 8, n=49,32,33,34,28,29,32,31,33,31 | -14.4 Picomoles per liter (pmol/L) | Standard Deviation 104.76 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 5, n=47,31,32,33,27,28,31,30,33,30 | -8.4 Picomoles per liter (pmol/L) | Standard Deviation 75.38 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 12, n=49,32,33,34,28,29,32,31,33,33 | 0.2 Picomoles per liter (pmol/L) | Standard Deviation 90.27 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 8, n=49,32,33,34,28,29,32,31,33,31 | -16.8 Picomoles per liter (pmol/L) | Standard Deviation 84.12 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 16, n=49,32,33,34,28,29,32,31,33,33 | -17.4 Picomoles per liter (pmol/L) | Standard Deviation 80.04 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 5, n=47,31,32,33,27,28,31,30,33,30 | 11.1 Picomoles per liter (pmol/L) | Standard Deviation 97.92 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 16, n=49,32,33,34,28,29,32,31,33,33 | 12.9 Picomoles per liter (pmol/L) | Standard Deviation 72.22 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 8, n=49,32,33,34,28,29,32,31,33,31 | 12.9 Picomoles per liter (pmol/L) | Standard Deviation 92.97 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 12, n=49,32,33,34,28,29,32,31,33,33 | 38.0 Picomoles per liter (pmol/L) | Standard Deviation 158.33 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 12, n=49,32,33,34,28,29,32,31,33,33 | 11.6 Picomoles per liter (pmol/L) | Standard Deviation 73.33 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 5, n=47,31,32,33,27,28,31,30,33,30 | 36.2 Picomoles per liter (pmol/L) | Standard Deviation 115.31 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 16, n=49,32,33,34,28,29,32,31,33,33 | 18.4 Picomoles per liter (pmol/L) | Standard Deviation 80.83 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16 | Week 8, n=49,32,33,34,28,29,32,31,33,31 | 6.6 Picomoles per liter (pmol/L) | Standard Deviation 62.9 |
Secondary
Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16
The FPG test measures blood sugar levels after the participant has not eaten (fasted) for at least eight hours prior to the sampling. The Baseline FPG value is the last non-missing value before the start of treatment. Change from Baseline in FPG was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Time frame: Baseline and Weeks 4, 5, 7, 8, 9, 12, 15, and 16
Population: ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 7, n=47,33,32,32,29,28,32,32,34,33 | -0.19 Millimoles per liter (mmol/L) | Standard Deviation 2.924 |
| Placebo | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 5, n=47,33,32,32,29,28,32,32,34,32 | -0.40 Millimoles per liter (mmol/L) | Standard Deviation 2.774 |
| Placebo | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 4, n=47,33,32,32,29,28,32,32,34,32 | -0.40 Millimoles per liter (mmol/L) | Standard Deviation 2.565 |
| Placebo | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 8, n=47,33,32,32,29,28,32,32,34,33 | -0.44 Millimoles per liter (mmol/L) | Standard Deviation 2.689 |
| Placebo | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 9, n=47,33,32,32,29,28,32,32,34,33 | -0.25 Millimoles per liter (mmol/L) | Standard Deviation 3.185 |
| Placebo | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 12, n=47,33,32,32,29,28,32,32,34,33 | -0.27 Millimoles per liter (mmol/L) | Standard Deviation 2.833 |
| Placebo | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 15, n=47,33,32,32,29,28,32,32,34,33 | -0.44 Millimoles per liter (mmol/L) | Standard Deviation 2.733 |
| Placebo | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 16, n=47,33,32,32,29,28,32,32,34,33 | -0.10 Millimoles per liter (mmol/L) | Standard Deviation 2.895 |
| Exenatide BID | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 12, n=47,33,32,32,29,28,32,32,34,33 | -1.32 Millimoles per liter (mmol/L) | Standard Deviation 2.518 |
| Exenatide BID | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 9, n=47,33,32,32,29,28,32,32,34,33 | -1.54 Millimoles per liter (mmol/L) | Standard Deviation 2.044 |
| Exenatide BID | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 16, n=47,33,32,32,29,28,32,32,34,33 | -0.80 Millimoles per liter (mmol/L) | Standard Deviation 2.482 |
| Exenatide BID | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 7, n=47,33,32,32,29,28,32,32,34,33 | -1.25 Millimoles per liter (mmol/L) | Standard Deviation 2.204 |
| Exenatide BID | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 4, n=47,33,32,32,29,28,32,32,34,32 | -1.11 Millimoles per liter (mmol/L) | Standard Deviation 1.953 |
| Exenatide BID | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 5, n=47,33,32,32,29,28,32,32,34,32 | -1.06 Millimoles per liter (mmol/L) | Standard Deviation 2.377 |
| Exenatide BID | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 15, n=47,33,32,32,29,28,32,32,34,33 | -1.27 Millimoles per liter (mmol/L) | Standard Deviation 2.343 |
| Exenatide BID | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 8, n=47,33,32,32,29,28,32,32,34,33 | -1.43 Millimoles per liter (mmol/L) | Standard Deviation 2.258 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 5, n=47,33,32,32,29,28,32,32,34,32 | -1.02 Millimoles per liter (mmol/L) | Standard Deviation 2.964 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 16, n=47,33,32,32,29,28,32,32,34,33 | -0.47 Millimoles per liter (mmol/L) | Standard Deviation 3.118 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 15, n=47,33,32,32,29,28,32,32,34,33 | -0.67 Millimoles per liter (mmol/L) | Standard Deviation 2.984 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 12, n=47,33,32,32,29,28,32,32,34,33 | -1.04 Millimoles per liter (mmol/L) | Standard Deviation 2.863 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 8, n=47,33,32,32,29,28,32,32,34,33 | -1.22 Millimoles per liter (mmol/L) | Standard Deviation 2.958 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 7, n=47,33,32,32,29,28,32,32,34,33 | -0.80 Millimoles per liter (mmol/L) | Standard Deviation 2.942 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 9, n=47,33,32,32,29,28,32,32,34,33 | -1.13 Millimoles per liter (mmol/L) | Standard Deviation 2.915 |
| Albiglutide 4 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 4, n=47,33,32,32,29,28,32,32,34,32 | -0.99 Millimoles per liter (mmol/L) | Standard Deviation 3.037 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 15, n=47,33,32,32,29,28,32,32,34,33 | -0.70 Millimoles per liter (mmol/L) | Standard Deviation 1.755 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 9, n=47,33,32,32,29,28,32,32,34,33 | -0.71 Millimoles per liter (mmol/L) | Standard Deviation 1.674 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 5, n=47,33,32,32,29,28,32,32,34,32 | -1.05 Millimoles per liter (mmol/L) | Standard Deviation 1.705 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 16, n=47,33,32,32,29,28,32,32,34,33 | -0.72 Millimoles per liter (mmol/L) | Standard Deviation 1.683 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 4, n=47,33,32,32,29,28,32,32,34,32 | -0.58 Millimoles per liter (mmol/L) | Standard Deviation 1.693 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 12, n=47,33,32,32,29,28,32,32,34,33 | -0.70 Millimoles per liter (mmol/L) | Standard Deviation 2.413 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 8, n=47,33,32,32,29,28,32,32,34,33 | -0.80 Millimoles per liter (mmol/L) | Standard Deviation 1.856 |
| Albiglutide 15 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 7, n=47,33,32,32,29,28,32,32,34,33 | -0.13 Millimoles per liter (mmol/L) | Standard Deviation 2.261 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 16, n=47,33,32,32,29,28,32,32,34,33 | -1.44 Millimoles per liter (mmol/L) | Standard Deviation 2.027 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 5, n=47,33,32,32,29,28,32,32,34,32 | -1.53 Millimoles per liter (mmol/L) | Standard Deviation 1.898 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 15, n=47,33,32,32,29,28,32,32,34,33 | -1.54 Millimoles per liter (mmol/L) | Standard Deviation 1.68 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 4, n=47,33,32,32,29,28,32,32,34,32 | -1.39 Millimoles per liter (mmol/L) | Standard Deviation 1.968 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 7, n=47,33,32,32,29,28,32,32,34,33 | -1.54 Millimoles per liter (mmol/L) | Standard Deviation 1.723 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 8, n=47,33,32,32,29,28,32,32,34,33 | -1.60 Millimoles per liter (mmol/L) | Standard Deviation 1.925 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 9, n=47,33,32,32,29,28,32,32,34,33 | -1.49 Millimoles per liter (mmol/L) | Standard Deviation 2.122 |
| Albiglutide 30 mg Weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 12, n=47,33,32,32,29,28,32,32,34,33 | -1.85 Millimoles per liter (mmol/L) | Standard Deviation 1.722 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 8, n=47,33,32,32,29,28,32,32,34,33 | -1.29 Millimoles per liter (mmol/L) | Standard Deviation 2.52 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 16, n=47,33,32,32,29,28,32,32,34,33 | -1.28 Millimoles per liter (mmol/L) | Standard Deviation 2.427 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 7, n=47,33,32,32,29,28,32,32,34,33 | -1.16 Millimoles per liter (mmol/L) | Standard Deviation 2.651 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 12, n=47,33,32,32,29,28,32,32,34,33 | -1.11 Millimoles per liter (mmol/L) | Standard Deviation 2.492 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 9, n=47,33,32,32,29,28,32,32,34,33 | -1.29 Millimoles per liter (mmol/L) | Standard Deviation 2.617 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 4, n=47,33,32,32,29,28,32,32,34,32 | -1.06 Millimoles per liter (mmol/L) | Standard Deviation 2.11 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 5, n=47,33,32,32,29,28,32,32,34,32 | -1.41 Millimoles per liter (mmol/L) | Standard Deviation 2.363 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 15, n=47,33,32,32,29,28,32,32,34,33 | -1.45 Millimoles per liter (mmol/L) | Standard Deviation 2.32 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 16, n=47,33,32,32,29,28,32,32,34,33 | -1.58 Millimoles per liter (mmol/L) | Standard Deviation 2.059 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 15, n=47,33,32,32,29,28,32,32,34,33 | -1.71 Millimoles per liter (mmol/L) | Standard Deviation 2.133 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 7, n=47,33,32,32,29,28,32,32,34,33 | -1.51 Millimoles per liter (mmol/L) | Standard Deviation 2.065 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 4, n=47,33,32,32,29,28,32,32,34,32 | -0.97 Millimoles per liter (mmol/L) | Standard Deviation 1.629 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 5, n=47,33,32,32,29,28,32,32,34,32 | -1.72 Millimoles per liter (mmol/L) | Standard Deviation 1.933 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 8, n=47,33,32,32,29,28,32,32,34,33 | -1.27 Millimoles per liter (mmol/L) | Standard Deviation 2.092 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 9, n=47,33,32,32,29,28,32,32,34,33 | -1.64 Millimoles per liter (mmol/L) | Standard Deviation 2.505 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 12, n=47,33,32,32,29,28,32,32,34,33 | -1.57 Millimoles per liter (mmol/L) | Standard Deviation 2.196 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 4, n=47,33,32,32,29,28,32,32,34,32 | -1.35 Millimoles per liter (mmol/L) | Standard Deviation 2.533 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 5, n=47,33,32,32,29,28,32,32,34,32 | -2.17 Millimoles per liter (mmol/L) | Standard Deviation 2.453 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 7, n=47,33,32,32,29,28,32,32,34,33 | -1.87 Millimoles per liter (mmol/L) | Standard Deviation 2.801 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 8, n=47,33,32,32,29,28,32,32,34,33 | -1.29 Millimoles per liter (mmol/L) | Standard Deviation 2.655 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 9, n=47,33,32,32,29,28,32,32,34,33 | -1.68 Millimoles per liter (mmol/L) | Standard Deviation 3.012 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 16, n=47,33,32,32,29,28,32,32,34,33 | -1.32 Millimoles per liter (mmol/L) | Standard Deviation 3.523 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 12, n=47,33,32,32,29,28,32,32,34,33 | -1.49 Millimoles per liter (mmol/L) | Standard Deviation 2.908 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 15, n=47,33,32,32,29,28,32,32,34,33 | -1.66 Millimoles per liter (mmol/L) | Standard Deviation 3.662 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 15, n=47,33,32,32,29,28,32,32,34,33 | -0.79 Millimoles per liter (mmol/L) | Standard Deviation 2.757 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 8, n=47,33,32,32,29,28,32,32,34,33 | -0.66 Millimoles per liter (mmol/L) | Standard Deviation 2.202 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 12, n=47,33,32,32,29,28,32,32,34,33 | -0.49 Millimoles per liter (mmol/L) | Standard Deviation 3.103 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 7, n=47,33,32,32,29,28,32,32,34,33 | -0.41 Millimoles per liter (mmol/L) | Standard Deviation 2.844 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 4, n=47,33,32,32,29,28,32,32,34,32 | -0.14 Millimoles per liter (mmol/L) | Standard Deviation 3.192 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 5, n=47,33,32,32,29,28,32,32,34,32 | -1.55 Millimoles per liter (mmol/L) | Standard Deviation 3.032 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 9, n=47,33,32,32,29,28,32,32,34,33 | -1.48 Millimoles per liter (mmol/L) | Standard Deviation 2.887 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 16, n=47,33,32,32,29,28,32,32,34,33 | -0.72 Millimoles per liter (mmol/L) | Standard Deviation 2.765 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 8, n=47,33,32,32,29,28,32,32,34,33 | -1.29 Millimoles per liter (mmol/L) | Standard Deviation 2.898 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 9, n=47,33,32,32,29,28,32,32,34,33 | -2.25 Millimoles per liter (mmol/L) | Standard Deviation 2.388 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 15, n=47,33,32,32,29,28,32,32,34,33 | -1.27 Millimoles per liter (mmol/L) | Standard Deviation 3.502 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 16, n=47,33,32,32,29,28,32,32,34,33 | -1.22 Millimoles per liter (mmol/L) | Standard Deviation 3.497 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 12, n=47,33,32,32,29,28,32,32,34,33 | -1.50 Millimoles per liter (mmol/L) | Standard Deviation 3.31 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 7, n=47,33,32,32,29,28,32,32,34,33 | -1.07 Millimoles per liter (mmol/L) | Standard Deviation 2.519 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 5, n=47,33,32,32,29,28,32,32,34,32 | -2.12 Millimoles per liter (mmol/L) | Standard Deviation 1.959 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 4, n=47,33,32,32,29,28,32,32,34,32 | -0.61 Millimoles per liter (mmol/L) | Standard Deviation 2.267 |
Secondary
Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16
The FLIE questionnaire is used to record the participant's feelings/opinions concerning the effects of nausea/vomiting on their quality of life during the past five days. Participants completed the questionnaire by responding to 18 questions. The first set of 9 questions refer to nausea, and the second set of 9 questions refer to vomiting. Each question is scored on a seven-point visual analog scale (1 to 7). On this scale, a score of 1 corresponds to 0 millimeters (mm), and a score of 7 correspond to 100 mm. Anything in between is marked at the appropriate point on the scale and is measured in mm. Data are reported in mm in this table. In FLIE questions (FLIEQ) 1, 2, 4, 5, 7, 8, 9, 10, 12, 13, 14, 16, and 17, a score of 1 indicates no effect on the quality of life, and a score of 7 indicates a great effect on the quality of life. In FLIEQ 3, 6, 11, 15, and 18, a score of 1 indicates a great effect on the quality of life, and a score of 7 indicates no effect on the quality of life.
Time frame: Baseline and Week 16
Population: Safety Population: all randomly assigned participants who received at least one dose of study drug. Only those participants available at the specified time point were analyzed. Change from Baseline was calculated as the score at Week 16 minus the score at Baseline.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ17 | 0.1 Score on a scale | Standard Deviation 1.6 |
| Placebo | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ10 | -0.3 Score on a scale | Standard Deviation 3.27 |
| Placebo | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ9 | -0.1 Score on a scale | Standard Deviation 3.55 |
| Placebo | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ18 | 18.1 Score on a scale | Standard Deviation 37.82 |
| Placebo | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ2 | 0.2 Score on a scale | Standard Deviation 2.15 |
| Placebo | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ3 | 15.6 Score on a scale | Standard Deviation 36.34 |
| Placebo | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ16 | -0.4 Score on a scale | Standard Deviation 2.58 |
| Placebo | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ4 | 0.4 Score on a scale | Standard Deviation 2.06 |
| Placebo | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ15 | 15.5 Score on a scale | Standard Deviation 36.06 |
| Placebo | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ5 | -0.3 Score on a scale | Standard Deviation 3.46 |
| Placebo | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ14 | -0.3 Score on a scale | Standard Deviation 2.95 |
| Placebo | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ6 | 11.2 Score on a scale | Standard Deviation 38.64 |
| Placebo | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ1 | -0.1 Score on a scale | Standard Deviation 6.79 |
| Placebo | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ13 | 0.1 Score on a scale | Standard Deviation 1.57 |
| Placebo | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ12 | 0.1 Score on a scale | Standard Deviation 1.52 |
| Placebo | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ7 | 0.4 Score on a scale | Standard Deviation 2.2 |
| Placebo | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ11 | 15.3 Score on a scale | Standard Deviation 36.17 |
| Placebo | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ8 | -0.6 Score on a scale | Standard Deviation 4.46 |
| Exenatide BID | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ12 | -3.1 Score on a scale | Standard Deviation 17.45 |
| Exenatide BID | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ10 | -4.9 Score on a scale | Standard Deviation 18.81 |
| Exenatide BID | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ3 | 7.8 Score on a scale | Standard Deviation 25.52 |
| Exenatide BID | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ14 | -4.1 Score on a scale | Standard Deviation 18.18 |
| Exenatide BID | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ16 | -3.8 Score on a scale | Standard Deviation 18.2 |
| Exenatide BID | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ6 | 3.6 Score on a scale | Standard Deviation 29.76 |
| Exenatide BID | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ5 | -4.0 Score on a scale | Standard Deviation 18.21 |
| Exenatide BID | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ11 | 3.3 Score on a scale | Standard Deviation 30.36 |
| Exenatide BID | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ17 | -4.1 Score on a scale | Standard Deviation 18.14 |
| Exenatide BID | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ13 | -4.0 Score on a scale | Standard Deviation 18.31 |
| Exenatide BID | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ2 | -3.5 Score on a scale | Standard Deviation 18.64 |
| Exenatide BID | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ1 | -4.4 Score on a scale | Standard Deviation 19.25 |
| Exenatide BID | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ8 | -3.5 Score on a scale | Standard Deviation 18.6 |
| Exenatide BID | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ4 | -3.5 Score on a scale | Standard Deviation 18.32 |
| Exenatide BID | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ7 | -3.1 Score on a scale | Standard Deviation 19.16 |
| Exenatide BID | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ18 | 6.9 Score on a scale | Standard Deviation 23.47 |
| Exenatide BID | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ9 | -3.4 Score on a scale | Standard Deviation 17.86 |
| Exenatide BID | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ15 | 7.0 Score on a scale | Standard Deviation 23.57 |
| Albiglutide 4 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ18 | 14.2 Score on a scale | Standard Deviation 33.91 |
| Albiglutide 4 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ3 | 10.3 Score on a scale | Standard Deviation 42.11 |
| Albiglutide 4 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ1 | 5.7 Score on a scale | Standard Deviation 23.42 |
| Albiglutide 4 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ16 | 6.3 Score on a scale | Standard Deviation 23.02 |
| Albiglutide 4 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ7 | 5.7 Score on a scale | Standard Deviation 23.46 |
| Albiglutide 4 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ15 | 14.2 Score on a scale | Standard Deviation 34.03 |
| Albiglutide 4 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ4 | 6.4 Score on a scale | Standard Deviation 24.11 |
| Albiglutide 4 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ14 | 6.4 Score on a scale | Standard Deviation 23.12 |
| Albiglutide 4 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ5 | 6.4 Score on a scale | Standard Deviation 23.09 |
| Albiglutide 4 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ11 | 13.8 Score on a scale | Standard Deviation 34.1 |
| Albiglutide 4 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ13 | 6.3 Score on a scale | Standard Deviation 23.03 |
| Albiglutide 4 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ6 | 9.4 Score on a scale | Standard Deviation 40.77 |
| Albiglutide 4 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ8 | 5.7 Score on a scale | Standard Deviation 23.36 |
| Albiglutide 4 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ10 | 5.8 Score on a scale | Standard Deviation 22.7 |
| Albiglutide 4 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ12 | 6.4 Score on a scale | Standard Deviation 23 |
| Albiglutide 4 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ9 | 5.3 Score on a scale | Standard Deviation 23.45 |
| Albiglutide 4 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ2 | 5.5 Score on a scale | Standard Deviation 23.42 |
| Albiglutide 4 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ17 | 6.3 Score on a scale | Standard Deviation 22.97 |
| Albiglutide 15 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ12 | -0.8 Score on a scale | Standard Deviation 8.09 |
| Albiglutide 15 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ16 | -1.4 Score on a scale | Standard Deviation 7.37 |
| Albiglutide 15 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ14 | -1.4 Score on a scale | Standard Deviation 6.22 |
| Albiglutide 15 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ2 | 2.6 Score on a scale | Standard Deviation 18.2 |
| Albiglutide 15 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ9 | -0.5 Score on a scale | Standard Deviation 3.64 |
| Albiglutide 15 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ3 | -4.0 Score on a scale | Standard Deviation 19.64 |
| Albiglutide 15 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ18 | -3.2 Score on a scale | Standard Deviation 17.62 |
| Albiglutide 15 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ1 | 1.0 Score on a scale | Standard Deviation 19.54 |
| Albiglutide 15 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ4 | -2.8 Score on a scale | Standard Deviation 11.95 |
| Albiglutide 15 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ8 | -1.0 Score on a scale | Standard Deviation 10.95 |
| Albiglutide 15 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ17 | -1.2 Score on a scale | Standard Deviation 6.08 |
| Albiglutide 15 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ13 | -2.2 Score on a scale | Standard Deviation 8.43 |
| Albiglutide 15 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ5 | -1.8 Score on a scale | Standard Deviation 7.18 |
| Albiglutide 15 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ11 | -0.5 Score on a scale | Standard Deviation 38.39 |
| Albiglutide 15 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ7 | 1.5 Score on a scale | Standard Deviation 16.77 |
| Albiglutide 15 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ6 | -0.5 Score on a scale | Standard Deviation 26.11 |
| Albiglutide 15 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ15 | -4.9 Score on a scale | Standard Deviation 18.87 |
| Albiglutide 15 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ10 | -1.6 Score on a scale | Standard Deviation 6.51 |
| Albiglutide 30 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ5 | 2.9 Score on a scale | Standard Deviation 11.23 |
| Albiglutide 30 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ1 | 4.6 Score on a scale | Standard Deviation 11.35 |
| Albiglutide 30 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ2 | 3.0 Score on a scale | Standard Deviation 11.67 |
| Albiglutide 30 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ3 | 18.6 Score on a scale | Standard Deviation 47.37 |
| Albiglutide 30 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ4 | 1.5 Score on a scale | Standard Deviation 5.16 |
| Albiglutide 30 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ6 | 20.0 Score on a scale | Standard Deviation 44.44 |
| Albiglutide 30 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ7 | 0.2 Score on a scale | Standard Deviation 0.69 |
| Albiglutide 30 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ8 | 2.6 Score on a scale | Standard Deviation 9.8 |
| Albiglutide 30 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ9 | 2.3 Score on a scale | Standard Deviation 8.7 |
| Albiglutide 30 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ10 | -0.1 Score on a scale | Standard Deviation 3.55 |
| Albiglutide 30 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ11 | 21.9 Score on a scale | Standard Deviation 42.11 |
| Albiglutide 30 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ12 | 1.8 Score on a scale | Standard Deviation 6.4 |
| Albiglutide 30 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ13 | 1.0 Score on a scale | Standard Deviation 6.12 |
| Albiglutide 30 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ14 | 1.8 Score on a scale | Standard Deviation 6.15 |
| Albiglutide 30 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ15 | 19.7 Score on a scale | Standard Deviation 46.48 |
| Albiglutide 30 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ16 | -0.5 Score on a scale | Standard Deviation 3.66 |
| Albiglutide 30 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ17 | -1.2 Score on a scale | Standard Deviation 5.1 |
| Albiglutide 30 mg Weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ18 | 14.9 Score on a scale | Standard Deviation 34.45 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ7 | 5.7 Score on a scale | Standard Deviation 22.88 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ8 | 10.1 Score on a scale | Standard Deviation 29.33 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ4 | 5.6 Score on a scale | Standard Deviation 22.91 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ15 | 5.6 Score on a scale | Standard Deviation 50.36 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ1 | 8.6 Score on a scale | Standard Deviation 24.35 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ12 | 5.3 Score on a scale | Standard Deviation 22.95 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ18 | 10.1 Score on a scale | Standard Deviation 45.39 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ11 | 7.9 Score on a scale | Standard Deviation 46.96 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ14 | 5.3 Score on a scale | Standard Deviation 22.94 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ16 | 8.2 Score on a scale | Standard Deviation 25.92 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ6 | 10.2 Score on a scale | Standard Deviation 45.38 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ10 | 4.5 Score on a scale | Standard Deviation 23.37 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ5 | 0.2 Score on a scale | Standard Deviation 33.34 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ9 | 5.6 Score on a scale | Standard Deviation 22.91 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ3 | 10.3 Score on a scale | Standard Deviation 45.34 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ13 | 9.8 Score on a scale | Standard Deviation 29.41 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ17 | 4.5 Score on a scale | Standard Deviation 23.36 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ2 | 5.9 Score on a scale | Standard Deviation 22.87 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ17 | -0.2 Score on a scale | Standard Deviation 1.98 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ15 | 3.5 Score on a scale | Standard Deviation 19.32 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ18 | 7.1 Score on a scale | Standard Deviation 26.96 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ7 | -1.0 Score on a scale | Standard Deviation 6.71 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ14 | -0.1 Score on a scale | Standard Deviation 1.61 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ4 | -1.6 Score on a scale | Standard Deviation 8.84 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ1 | -1.0 Score on a scale | Standard Deviation 2.22 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ11 | 3.6 Score on a scale | Standard Deviation 19.32 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ10 | -0.3 Score on a scale | Standard Deviation 1.81 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ2 | -0.8 Score on a scale | Standard Deviation 4.03 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ8 | -0.7 Score on a scale | Standard Deviation 3.14 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ6 | 4.2 Score on a scale | Standard Deviation 31.38 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ12 | -0.2 Score on a scale | Standard Deviation 2.26 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ9 | -0.7 Score on a scale | Standard Deviation 3.2 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ16 | -0.1 Score on a scale | Standard Deviation 1.8 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ5 | -1.3 Score on a scale | Standard Deviation 5.41 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ13 | -0.3 Score on a scale | Standard Deviation 1.71 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ3 | 3.9 Score on a scale | Standard Deviation 32.47 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ16 | 4.5 Score on a scale | Standard Deviation 21.95 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ1 | 8.2 Score on a scale | Standard Deviation 22.66 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ10 | 4.3 Score on a scale | Standard Deviation 22 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ7 | 4.9 Score on a scale | Standard Deviation 21.93 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ11 | 18.3 Score on a scale | Standard Deviation 40.27 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ6 | 18.0 Score on a scale | Standard Deviation 40.06 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ12 | 4.4 Score on a scale | Standard Deviation 21.97 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ5 | 4.5 Score on a scale | Standard Deviation 21.97 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ13 | 4.3 Score on a scale | Standard Deviation 22.02 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ2 | 4.7 Score on a scale | Standard Deviation 21.95 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ4 | 5.9 Score on a scale | Standard Deviation 22.48 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ14 | 4.3 Score on a scale | Standard Deviation 22 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ15 | 18.4 Score on a scale | Standard Deviation 40.22 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ3 | 18.2 Score on a scale | Standard Deviation 39.83 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ18 | 18.5 Score on a scale | Standard Deviation 40.09 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ17 | 4.3 Score on a scale | Standard Deviation 22.02 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ9 | 4.0 Score on a scale | Standard Deviation 22.33 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ8 | 6.2 Score on a scale | Standard Deviation 22.05 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ13 | 0.0 Score on a scale | Standard Deviation 1.72 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ9 | -0.1 Score on a scale | Standard Deviation 4.63 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ18 | 5.7 Score on a scale | Standard Deviation 26.48 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ11 | 7.2 Score on a scale | Standard Deviation 25.77 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ7 | -0.1 Score on a scale | Standard Deviation 4.85 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ10 | 0.2 Score on a scale | Standard Deviation 1.9 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ17 | -1.1 Score on a scale | Standard Deviation 5.62 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ12 | -0.4 Score on a scale | Standard Deviation 3.17 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ6 | 5.6 Score on a scale | Standard Deviation 26.54 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ8 | -0.4 Score on a scale | Standard Deviation 4.91 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ1 | -0.3 Score on a scale | Standard Deviation 7.18 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ16 | 0.9 Score on a scale | Standard Deviation 5.55 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ5 | 1.5 Score on a scale | Standard Deviation 6.42 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ14 | -0.1 Score on a scale | Standard Deviation 1.81 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ2 | -0.6 Score on a scale | Standard Deviation 3.21 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ3 | 4.5 Score on a scale | Standard Deviation 28.67 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ4 | -1.9 Score on a scale | Standard Deviation 16.9 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ15 | 1.5 Score on a scale | Standard Deviation 20.48 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ4 | -1.8 Score on a scale | Standard Deviation 6.68 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ15 | 4.0 Score on a scale | Standard Deviation 36.71 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ7 | -1.9 Score on a scale | Standard Deviation 6.44 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ18 | 6.9 Score on a scale | Standard Deviation 30.76 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ5 | -1.4 Score on a scale | Standard Deviation 6.03 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ2 | -0.2 Score on a scale | Standard Deviation 1.84 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ12 | -0.8 Score on a scale | Standard Deviation 3.49 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ16 | -1.5 Score on a scale | Standard Deviation 4.32 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ6 | 3.9 Score on a scale | Standard Deviation 36.69 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ11 | 4.0 Score on a scale | Standard Deviation 36.47 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ1 | -2.8 Score on a scale | Standard Deviation 8.3 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ9 | -3.2 Score on a scale | Standard Deviation 9.8 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ17 | -0.6 Score on a scale | Standard Deviation 3.89 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ8 | -2.3 Score on a scale | Standard Deviation 7.08 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ10 | -2.0 Score on a scale | Standard Deviation 5.12 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ14 | -2.1 Score on a scale | Standard Deviation 6.36 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ3 | 7.3 Score on a scale | Standard Deviation 29.72 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16 | FLIEQ13 | -2.1 Score on a scale | Standard Deviation 6.55 |
Secondary
Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline in HbA1c was calculated as the post-Baseline value minus the value at Baseline. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Time frame: Baseline and Weeks 4, 5, 7, 8, 9, 12, 15, and 16
Population: ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 7, n=50,34,34,34,29,30,32,34,35,32 | -0.15 Percentage of HbA1c in the blood | Standard Deviation 0.749 |
| Placebo | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 5, n=49,34,34,34,29,30,32,34,35,31 | -0.09 Percentage of HbA1c in the blood | Standard Deviation 0.57 |
| Placebo | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 4, n=47,34,33,34,28,29,31,34,34,30 | -0.14 Percentage of HbA1c in the blood | Standard Deviation 0.538 |
| Placebo | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 8, n=50,34,34,34,29,30,32,34,35,32 | -0.17 Percentage of HbA1c in the blood | Standard Deviation 0.793 |
| Placebo | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 9, n=50,34,34,34,29,30,32,34,35,32 | -0.21 Percentage of HbA1c in the blood | Standard Deviation 0.842 |
| Placebo | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 12, n=50,34,34,34,29,30,32,34,35,33 | -0.19 Percentage of HbA1c in the blood | Standard Deviation 0.892 |
| Placebo | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 15, n=50,34,34,34,29,30,32,34,35,33 | -0.27 Percentage of HbA1c in the blood | Standard Deviation 0.948 |
| Placebo | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 16, n=50,34,34,34,29,30,32,34,35,33 | -0.17 Percentage of HbA1c in the blood | Standard Deviation 1.006 |
| Exenatide BID | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 12, n=50,34,34,34,29,30,32,34,35,33 | -0.56 Percentage of HbA1c in the blood | Standard Deviation 0.868 |
| Exenatide BID | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 9, n=50,34,34,34,29,30,32,34,35,32 | -0.51 Percentage of HbA1c in the blood | Standard Deviation 0.633 |
| Exenatide BID | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 16, n=50,34,34,34,29,30,32,34,35,33 | -0.54 Percentage of HbA1c in the blood | Standard Deviation 0.906 |
| Exenatide BID | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 7, n=50,34,34,34,29,30,32,34,35,32 | -0.36 Percentage of HbA1c in the blood | Standard Deviation 0.554 |
| Exenatide BID | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 4, n=47,34,33,34,28,29,31,34,34,30 | -0.23 Percentage of HbA1c in the blood | Standard Deviation 0.485 |
| Exenatide BID | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 5, n=49,34,34,34,29,30,32,34,35,31 | -0.32 Percentage of HbA1c in the blood | Standard Deviation 0.495 |
| Exenatide BID | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 15, n=50,34,34,34,29,30,32,34,35,33 | -0.53 Percentage of HbA1c in the blood | Standard Deviation 0.865 |
| Exenatide BID | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 8, n=50,34,34,34,29,30,32,34,35,32 | -0.45 Percentage of HbA1c in the blood | Standard Deviation 0.588 |
| Albiglutide 4 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 5, n=49,34,34,34,29,30,32,34,35,31 | -0.16 Percentage of HbA1c in the blood | Standard Deviation 0.758 |
| Albiglutide 4 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 16, n=50,34,34,34,29,30,32,34,35,33 | -0.11 Percentage of HbA1c in the blood | Standard Deviation 1.156 |
| Albiglutide 4 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 15, n=50,34,34,34,29,30,32,34,35,33 | -0.19 Percentage of HbA1c in the blood | Standard Deviation 0.989 |
| Albiglutide 4 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 12, n=50,34,34,34,29,30,32,34,35,33 | -0.18 Percentage of HbA1c in the blood | Standard Deviation 1.025 |
| Albiglutide 4 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 8, n=50,34,34,34,29,30,32,34,35,32 | -0.24 Percentage of HbA1c in the blood | Standard Deviation 0.897 |
| Albiglutide 4 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 7, n=50,34,34,34,29,30,32,34,35,32 | -0.19 Percentage of HbA1c in the blood | Standard Deviation 0.855 |
| Albiglutide 4 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 9, n=50,34,34,34,29,30,32,34,35,32 | -0.19 Percentage of HbA1c in the blood | Standard Deviation 0.947 |
| Albiglutide 4 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 4, n=47,34,33,34,28,29,31,34,34,30 | -0.12 Percentage of HbA1c in the blood | Standard Deviation 0.658 |
| Albiglutide 15 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 15, n=50,34,34,34,29,30,32,34,35,33 | -0.49 Percentage of HbA1c in the blood | Standard Deviation 0.819 |
| Albiglutide 15 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 9, n=50,34,34,34,29,30,32,34,35,32 | -0.55 Percentage of HbA1c in the blood | Standard Deviation 0.713 |
| Albiglutide 15 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 5, n=49,34,34,34,29,30,32,34,35,31 | -0.39 Percentage of HbA1c in the blood | Standard Deviation 0.516 |
| Albiglutide 15 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 16, n=50,34,34,34,29,30,32,34,35,33 | -0.49 Percentage of HbA1c in the blood | Standard Deviation 0.74 |
| Albiglutide 15 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 4, n=47,34,33,34,28,29,31,34,34,30 | -0.33 Percentage of HbA1c in the blood | Standard Deviation 0.442 |
| Albiglutide 15 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 12, n=50,34,34,34,29,30,32,34,35,33 | -0.58 Percentage of HbA1c in the blood | Standard Deviation 0.813 |
| Albiglutide 15 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 8, n=50,34,34,34,29,30,32,34,35,32 | -0.50 Percentage of HbA1c in the blood | Standard Deviation 0.659 |
| Albiglutide 15 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 7, n=50,34,34,34,29,30,32,34,35,32 | -0.44 Percentage of HbA1c in the blood | Standard Deviation 0.619 |
| Albiglutide 30 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 16, n=50,34,34,34,29,30,32,34,35,33 | -0.87 Percentage of HbA1c in the blood | Standard Deviation 0.652 |
| Albiglutide 30 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 5, n=49,34,34,34,29,30,32,34,35,31 | -0.62 Percentage of HbA1c in the blood | Standard Deviation 0.439 |
| Albiglutide 30 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 15, n=50,34,34,34,29,30,32,34,35,33 | -0.86 Percentage of HbA1c in the blood | Standard Deviation 0.607 |
| Albiglutide 30 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 4, n=47,34,33,34,28,29,31,34,34,30 | -0.56 Percentage of HbA1c in the blood | Standard Deviation 0.401 |
| Albiglutide 30 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 7, n=50,34,34,34,29,30,32,34,35,32 | -0.79 Percentage of HbA1c in the blood | Standard Deviation 0.474 |
| Albiglutide 30 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 8, n=50,34,34,34,29,30,32,34,35,32 | -0.77 Percentage of HbA1c in the blood | Standard Deviation 0.494 |
| Albiglutide 30 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 9, n=50,34,34,34,29,30,32,34,35,32 | -0.85 Percentage of HbA1c in the blood | Standard Deviation 0.559 |
| Albiglutide 30 mg Weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 12, n=50,34,34,34,29,30,32,34,35,33 | -0.96 Percentage of HbA1c in the blood | Standard Deviation 0.649 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 8, n=50,34,34,34,29,30,32,34,35,32 | -0.54 Percentage of HbA1c in the blood | Standard Deviation 0.679 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 16, n=50,34,34,34,29,30,32,34,35,33 | -0.56 Percentage of HbA1c in the blood | Standard Deviation 0.971 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 7, n=50,34,34,34,29,30,32,34,35,32 | -0.52 Percentage of HbA1c in the blood | Standard Deviation 0.648 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 12, n=50,34,34,34,29,30,32,34,35,33 | -0.59 Percentage of HbA1c in the blood | Standard Deviation 0.913 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 9, n=50,34,34,34,29,30,32,34,35,32 | -0.56 Percentage of HbA1c in the blood | Standard Deviation 0.767 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 4, n=47,34,33,34,28,29,31,34,34,30 | -0.35 Percentage of HbA1c in the blood | Standard Deviation 0.47 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 5, n=49,34,34,34,29,30,32,34,35,31 | -0.42 Percentage of HbA1c in the blood | Standard Deviation 0.625 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 15, n=50,34,34,34,29,30,32,34,35,33 | -0.61 Percentage of HbA1c in the blood | Standard Deviation 0.929 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 16, n=50,34,34,34,29,30,32,34,35,33 | -0.79 Percentage of HbA1c in the blood | Standard Deviation 0.978 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 15, n=50,34,34,34,29,30,32,34,35,33 | -0.79 Percentage of HbA1c in the blood | Standard Deviation 1.044 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 7, n=50,34,34,34,29,30,32,34,35,32 | 0.64 Percentage of HbA1c in the blood | Standard Deviation 0.89 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 4, n=47,34,33,34,28,29,31,34,34,30 | -0.34 Percentage of HbA1c in the blood | Standard Deviation 0.678 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 5, n=49,34,34,34,29,30,32,34,35,31 | -0.51 Percentage of HbA1c in the blood | Standard Deviation 0.756 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 8, n=50,34,34,34,29,30,32,34,35,32 | -0.67 Percentage of HbA1c in the blood | Standard Deviation 0.928 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 9, n=50,34,34,34,29,30,32,34,35,32 | -0.71 Percentage of HbA1c in the blood | Standard Deviation 0.929 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 12, n=50,34,34,34,29,30,32,34,35,33 | -0.71 Percentage of HbA1c in the blood | Standard Deviation 1.003 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 4, n=47,34,33,34,28,29,31,34,34,30 | -0.45 Percentage of HbA1c in the blood | Standard Deviation 0.547 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 5, n=49,34,34,34,29,30,32,34,35,31 | -0.58 Percentage of HbA1c in the blood | Standard Deviation 0.554 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 7, n=50,34,34,34,29,30,32,34,35,32 | -0.68 Percentage of HbA1c in the blood | Standard Deviation 0.831 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 8, n=50,34,34,34,29,30,32,34,35,32 | -0.71 Percentage of HbA1c in the blood | Standard Deviation 0.834 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 9, n=50,34,34,34,29,30,32,34,35,32 | -0.77 Percentage of HbA1c in the blood | Standard Deviation 0.842 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 16, n=50,34,34,34,29,30,32,34,35,33 | -0.79 Percentage of HbA1c in the blood | Standard Deviation 1.036 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 12, n=50,34,34,34,29,30,32,34,35,33 | -0.79 Percentage of HbA1c in the blood | Standard Deviation 0.852 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 15, n=50,34,34,34,29,30,32,34,35,33 | -0.80 Percentage of HbA1c in the blood | Standard Deviation 1.041 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 15, n=50,34,34,34,29,30,32,34,35,33 | -0.58 Percentage of HbA1c in the blood | Standard Deviation 1.016 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 8, n=50,34,34,34,29,30,32,34,35,32 | -0.41 Percentage of HbA1c in the blood | Standard Deviation 0.823 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 12, n=50,34,34,34,29,30,32,34,35,33 | -0.51 Percentage of HbA1c in the blood | Standard Deviation 0.942 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 7, n=50,34,34,34,29,30,32,34,35,32 | -0.45 Percentage of HbA1c in the blood | Standard Deviation 0.801 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 4, n=47,34,33,34,28,29,31,34,34,30 | -0.41 Percentage of HbA1c in the blood | Standard Deviation 0.429 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 5, n=49,34,34,34,29,30,32,34,35,31 | -0.47 Percentage of HbA1c in the blood | Standard Deviation 0.608 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 9, n=50,34,34,34,29,30,32,34,35,32 | -0.54 Percentage of HbA1c in the blood | Standard Deviation 0.836 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 16, n=50,34,34,34,29,30,32,34,35,33 | -0.55 Percentage of HbA1c in the blood | Standard Deviation 1.012 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 8, n=50,34,34,34,29,30,32,34,35,32 | -0.68 Percentage of HbA1c in the blood | Standard Deviation 0.41 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 9, n=50,34,34,34,29,30,32,34,35,32 | -0.82 Percentage of HbA1c in the blood | Standard Deviation 0.486 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 15, n=50,34,34,34,29,30,32,34,35,33 | -0.88 Percentage of HbA1c in the blood | Standard Deviation 0.79 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 16, n=50,34,34,34,29,30,32,34,35,33 | -0.87 Percentage of HbA1c in the blood | Standard Deviation 0.866 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 12, n=50,34,34,34,29,30,32,34,35,33 | -0.84 Percentage of HbA1c in the blood | Standard Deviation 0.744 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 7, n=50,34,34,34,29,30,32,34,35,32 | -0.63 Percentage of HbA1c in the blood | Standard Deviation 0.42 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 5, n=49,34,34,34,29,30,32,34,35,31 | -0.65 Percentage of HbA1c in the blood | Standard Deviation 0.376 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | Week 4, n=47,34,33,34,28,29,31,34,34,30 | -0.42 Percentage of HbA1c in the blood | Standard Deviation 0.523 |
Secondary
Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16
Serum lipid components, including triglycerides (TG), free fatty acids (FFA), total cholesterol (CL), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), were measured at Baseline and Weeks 5, 8, 12, and 16. The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Time frame: Baseline and Weeks 5, 8, 12, and 16
Population: ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed for different parameters at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.329 mmol/L | Standard Deviation 1.2941 |
| Placebo | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.050 mmol/L | Standard Deviation 0.5932 |
| Placebo | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.005 mmol/L | Standard Deviation 0.1192 |
| Placebo | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.377 mmol/L | Standard Deviation 1.6534 |
| Placebo | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.011 mmol/L | Standard Deviation 0.1341 |
| Placebo | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 12, n=50,34,34,34,28,30,32,34,35,33 | 0.045 mmol/L | Standard Deviation 0.6465 |
| Placebo | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 5, n=41,29,31,29,26,28,29,27,32,29 | 0.066 mmol/L | Standard Deviation 0.5417 |
| Placebo | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.225 mmol/L | Standard Deviation 1.0354 |
| Placebo | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 8, n=45,32,32,32,26,30,31,28,32,30 | 0.066 mmol/L | Standard Deviation 0.5123 |
| Placebo | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.023 mmol/L | Standard Deviation 0.6128 |
| Placebo | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 16, n=50,34,34,34,28,30,32,34,35,33 | 0.095 mmol/L | Standard Deviation 0.7695 |
| Placebo | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.222 mmol/L | Standard Deviation 1.559 |
| Placebo | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 12, n=45,33,32,32,28,30,31,28,32,32 | 0.138 mmol/L | Standard Deviation 0.4923 |
| Placebo | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 16, n=50,34,33,34,28,29,32,34,35,33 | 0.078 mmol/L | Standard Deviation 0.2047 |
| Placebo | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 16, n=46,33,32,32,28,30,31,28,32,32 | 0.190 mmol/L | Standard Deviation 0.6025 |
| Placebo | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 12, n=50,34,33,34,28,29,32,34,35,33 | 0.075 mmol/L | Standard Deviation 0.2018 |
| Placebo | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.002 mmol/L | Standard Deviation 0.1274 |
| Placebo | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 8, n=50,34,33,34,28,29,32,34,35,31 | 0.034 mmol/L | Standard Deviation 0.2021 |
| Placebo | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.020 mmol/L | Standard Deviation 0.1189 |
| Placebo | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 5, n=48,33,32,33,27,28,32,34,35,29 | 0.029 mmol/L | Standard Deviation 0.1867 |
| Exenatide BID | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 5, n=41,29,31,29,26,28,29,27,32,29 | -0.153 mmol/L | Standard Deviation 0.5479 |
| Exenatide BID | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 12, n=50,34,34,34,28,30,32,34,35,33 | 0.054 mmol/L | Standard Deviation 0.7723 |
| Exenatide BID | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.238 mmol/L | Standard Deviation 0.6205 |
| Exenatide BID | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.031 mmol/L | Standard Deviation 0.8271 |
| Exenatide BID | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 12, n=50,34,34,34,28,30,32,34,35,33 | 0.094 mmol/L | Standard Deviation 1.4597 |
| Exenatide BID | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.003 mmol/L | Standard Deviation 0.2269 |
| Exenatide BID | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.149 mmol/L | Standard Deviation 0.8423 |
| Exenatide BID | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.058 mmol/L | Standard Deviation 0.1606 |
| Exenatide BID | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 5, n=48,33,32,33,27,28,32,34,35,29 | -0.038 mmol/L | Standard Deviation 0.2518 |
| Exenatide BID | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.068 mmol/L | Standard Deviation 0.7288 |
| Exenatide BID | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.047 mmol/L | Standard Deviation 0.142 |
| Exenatide BID | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 8, n=50,34,33,34,28,29,32,34,35,31 | -0.045 mmol/L | Standard Deviation 0.2186 |
| Exenatide BID | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 16, n=46,33,32,32,28,30,31,28,32,32 | 0.096 mmol/L | Standard Deviation 0.696 |
| Exenatide BID | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 12, n=50,34,33,34,28,29,32,34,35,33 | -0.007 mmol/L | Standard Deviation 0.1882 |
| Exenatide BID | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 16, n=50,34,33,34,28,29,32,34,35,33 | -0.031 mmol/L | Standard Deviation 0.1631 |
| Exenatide BID | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 12, n=45,33,32,32,28,30,31,28,32,32 | 0.105 mmol/L | Standard Deviation 0.6259 |
| Exenatide BID | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.239 mmol/L | Standard Deviation 0.6613 |
| Exenatide BID | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.025 mmol/L | Standard Deviation 0.2192 |
| Exenatide BID | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 8, n=45,32,32,32,26,30,31,28,32,30 | -0.014 mmol/L | Standard Deviation 0.5556 |
| Exenatide BID | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.182 mmol/L | Standard Deviation 0.6517 |
| Albiglutide 4 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 5, n=45,31,34,31,27,29,31,34,35,30 | 0.303 mmol/L | Standard Deviation 2.1539 |
| Albiglutide 4 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 5, n=45,31,34,31,27,29,31,34,35,30 | 0.001 mmol/L | Standard Deviation 0.1203 |
| Albiglutide 4 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 12, n=50,34,33,34,28,29,32,34,35,33 | 0.022 mmol/L | Standard Deviation 0.2003 |
| Albiglutide 4 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 8, n=50,33,34,34,27,30,32,34,35,31 | 0.006 mmol/L | Standard Deviation 0.116 |
| Albiglutide 4 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.032 mmol/L | Standard Deviation 0.9312 |
| Albiglutide 4 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 12, n=50,34,34,34,28,30,32,34,35,33 | 0.221 mmol/L | Standard Deviation 2.3056 |
| Albiglutide 4 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 8, n=50,33,34,34,27,30,32,34,35,31 | 0.178 mmol/L | Standard Deviation 2.1883 |
| Albiglutide 4 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.007 mmol/L | Standard Deviation 0.1366 |
| Albiglutide 4 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 16, n=50,34,34,34,28,30,32,34,35,33 | 0.122 mmol/L | Standard Deviation 2.1274 |
| Albiglutide 4 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 12, n=45,33,32,32,28,30,31,28,32,32 | -0.096 mmol/L | Standard Deviation 0.6483 |
| Albiglutide 4 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.025 mmol/L | Standard Deviation 0.9136 |
| Albiglutide 4 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 16, n=50,34,33,34,28,29,32,34,35,33 | 0.020 mmol/L | Standard Deviation 0.2084 |
| Albiglutide 4 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 8, n=50,34,33,34,28,29,32,34,35,31 | 0.033 mmol/L | Standard Deviation 0.1699 |
| Albiglutide 4 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 5, n=41,29,31,29,26,28,29,27,32,29 | -0.294 mmol/L | Standard Deviation 0.7053 |
| Albiglutide 4 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 8, n=45,32,32,32,26,30,31,28,32,30 | -0.132 mmol/L | Standard Deviation 0.7398 |
| Albiglutide 4 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 12, n=50,34,34,34,28,30,32,34,35,33 | 0.004 mmol/L | Standard Deviation 0.1258 |
| Albiglutide 4 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.153 mmol/L | Standard Deviation 0.8765 |
| Albiglutide 4 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 5, n=48,33,32,33,27,28,32,34,35,29 | -0.032 mmol/L | Standard Deviation 0.1691 |
| Albiglutide 4 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 16, n=46,33,32,32,28,30,31,28,32,32 | -0.109 mmol/L | Standard Deviation 0.6558 |
| Albiglutide 4 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.060 mmol/L | Standard Deviation 0.9192 |
| Albiglutide 15 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.376 mmol/L | Standard Deviation 1.1387 |
| Albiglutide 15 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.037 mmol/L | Standard Deviation 0.5402 |
| Albiglutide 15 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 5, n=48,33,32,33,27,28,32,34,35,29 | -0.008 mmol/L | Standard Deviation 0.1392 |
| Albiglutide 15 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.010 mmol/L | Standard Deviation 0.1491 |
| Albiglutide 15 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.019 mmol/L | Standard Deviation 0.1115 |
| Albiglutide 15 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 8, n=50,34,33,34,28,29,32,34,35,31 | -0.048 mmol/L | Standard Deviation 0.1345 |
| Albiglutide 15 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 16, n=46,33,32,32,28,30,31,28,32,32 | -0.045 mmol/L | Standard Deviation 0.6183 |
| Albiglutide 15 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.162 mmol/L | Standard Deviation 0.4772 |
| Albiglutide 15 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 12, n=50,34,33,34,28,29,32,34,35,33 | -0.013 mmol/L | Standard Deviation 0.187 |
| Albiglutide 15 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.010 mmol/L | Standard Deviation 0.1342 |
| Albiglutide 15 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 12, n=45,33,32,32,28,30,31,28,32,32 | -0.152 mmol/L | Standard Deviation 0.6477 |
| Albiglutide 15 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.408 mmol/L | Standard Deviation 1.3143 |
| Albiglutide 15 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 16, n=50,34,33,34,28,29,32,34,35,33 | 0.016 mmol/L | Standard Deviation 0.2159 |
| Albiglutide 15 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.140 mmol/L | Standard Deviation 0.5686 |
| Albiglutide 15 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 8, n=45,32,32,32,26,30,31,28,32,30 | -0.157 mmol/L | Standard Deviation 0.562 |
| Albiglutide 15 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.139 mmol/L | Standard Deviation 0.5795 |
| Albiglutide 15 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 5, n=41,29,31,29,26,28,29,27,32,29 | -0.155 mmol/L | Standard Deviation 0.5653 |
| Albiglutide 15 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 8, n=50,33,34,34,27,30,32,34,35,31 | 0.019 mmol/L | Standard Deviation 0.1187 |
| Albiglutide 15 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.341 mmol/L | Standard Deviation 1.2139 |
| Albiglutide 15 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.296 mmol/L | Standard Deviation 1.2876 |
| Albiglutide 30 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 12, n=50,34,33,34,28,29,32,34,35,33 | 0.043 mmol/L | Standard Deviation 0.1826 |
| Albiglutide 30 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 5, n=41,29,31,29,26,28,29,27,32,29 | -0.068 mmol/L | Standard Deviation 0.6225 |
| Albiglutide 30 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 16, n=46,33,32,32,28,30,31,28,32,32 | 0.003 mmol/L | Standard Deviation 0.601 |
| Albiglutide 30 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 5, n=45,31,34,31,27,29,31,34,35,30 | 0.112 mmol/L | Standard Deviation 0.6974 |
| Albiglutide 30 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.113 mmol/L | Standard Deviation 0.6588 |
| Albiglutide 30 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.046 mmol/L | Standard Deviation 0.1699 |
| Albiglutide 30 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.020 mmol/L | Standard Deviation 0.6926 |
| Albiglutide 30 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 12, n=50,34,34,34,28,30,32,34,35,33 | 0.106 mmol/L | Standard Deviation 0.8936 |
| Albiglutide 30 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.061 mmol/L | Standard Deviation 0.1368 |
| Albiglutide 30 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 16, n=50,34,34,34,28,30,32,34,35,33 | 0.009 mmol/L | Standard Deviation 0.5964 |
| Albiglutide 30 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 5, n=48,33,32,33,27,28,32,34,35,29 | 0.014 mmol/L | Standard Deviation 0.1381 |
| Albiglutide 30 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 8, n=50,34,33,34,28,29,32,34,35,31 | 0.046 mmol/L | Standard Deviation 0.1934 |
| Albiglutide 30 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 8, n=50,33,34,34,27,30,32,34,35,31 | 0.002 mmol/L | Standard Deviation 0.587 |
| Albiglutide 30 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.061 mmol/L | Standard Deviation 0.1674 |
| Albiglutide 30 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 16, n=50,34,33,34,28,29,32,34,35,33 | 0.050 mmol/L | Standard Deviation 0.1695 |
| Albiglutide 30 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 12, n=45,33,32,32,28,30,31,28,32,32 | 0.004 mmol/L | Standard Deviation 0.6456 |
| Albiglutide 30 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.063 mmol/L | Standard Deviation 0.1425 |
| Albiglutide 30 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.009 mmol/L | Standard Deviation 0.6977 |
| Albiglutide 30 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 8, n=45,32,32,32,26,30,31,28,32,30 | 0.089 mmol/L | Standard Deviation 0.6053 |
| Albiglutide 30 mg Weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 16, n=50,34,34,34,28,30,32,34,35,33 | 0.099 mmol/L | Standard Deviation 0.9002 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 5, n=41,29,31,29,26,28,29,27,32,29 | -0.285 mmol/L | Standard Deviation 0.5345 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.266 mmol/L | Standard Deviation 1.2296 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.219 mmol/L | Standard Deviation 1.021 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.380 mmol/L | Standard Deviation 0.8947 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.258 mmol/L | Standard Deviation 0.9248 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 5, n=48,33,32,33,27,28,32,34,35,29 | 0.025 mmol/L | Standard Deviation 0.1927 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 8, n=50,34,33,34,28,29,32,34,35,31 | 0.017 mmol/L | Standard Deviation 0.1897 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 12, n=50,34,33,34,28,29,32,34,35,33 | 0.010 mmol/L | Standard Deviation 0.192 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 16, n=50,34,33,34,28,29,32,34,35,33 | 0.034 mmol/L | Standard Deviation 0.2006 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.372 mmol/L | Standard Deviation 0.6998 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.172 mmol/L | Standard Deviation 0.6633 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.190 mmol/L | Standard Deviation 0.5975 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.225 mmol/L | Standard Deviation 0.542 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 8, n=45,32,32,32,26,30,31,28,32,30 | -0.160 mmol/L | Standard Deviation 0.5305 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 12, n=45,33,32,32,28,30,31,28,32,32 | -0.034 mmol/L | Standard Deviation 0.5547 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 16, n=46,33,32,32,28,30,31,28,32,32 | -0.123 mmol/L | Standard Deviation 0.5198 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.038 mmol/L | Standard Deviation 0.1215 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.018 mmol/L | Standard Deviation 0.1417 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.018 mmol/L | Standard Deviation 0.1323 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.015 mmol/L | Standard Deviation 0.1146 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.092 mmol/L | Standard Deviation 0.8249 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 16, n=50,34,33,34,28,29,32,34,35,33 | -0.005 mmol/L | Standard Deviation 0.2494 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.041 mmol/L | Standard Deviation 0.1998 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 5, n=41,29,31,29,26,28,29,27,32,29 | -0.082 mmol/L | Standard Deviation 0.3708 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.045 mmol/L | Standard Deviation 0.1434 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.147 mmol/L | Standard Deviation 1.0251 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 12, n=45,33,32,32,28,30,31,28,32,32 | -0.004 mmol/L | Standard Deviation 0.7153 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.140 mmol/L | Standard Deviation 0.4168 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.150 mmol/L | Standard Deviation 0.961 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.094 mmol/L | Standard Deviation 0.4566 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 12, n=50,34,33,34,28,29,32,34,35,33 | -0.051 mmol/L | Standard Deviation 0.225 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.269 mmol/L | Standard Deviation 1.0358 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 5, n=48,33,32,33,27,28,32,34,35,29 | -0.028 mmol/L | Standard Deviation 0.2017 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 8, n=45,32,32,32,26,30,31,28,32,30 | -0.052 mmol/L | Standard Deviation 0.4403 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 8, n=50,34,33,34,28,29,32,34,35,31 | -0.027 mmol/L | Standard Deviation 0.1974 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.031 mmol/L | Standard Deviation 0.1413 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 16, n=46,33,32,32,28,30,31,28,32,32 | -0.062 mmol/L | Standard Deviation 0.3943 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.178 mmol/L | Standard Deviation 0.4476 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.331 mmol/L | Standard Deviation 0.9529 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.030 mmol/L | Standard Deviation 0.1217 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.050 mmol/L | Standard Deviation 0.1403 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.418 mmol/L | Standard Deviation 0.8572 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 5, n=48,33,32,33,27,28,32,34,35,29 | -0.012 mmol/L | Standard Deviation 0.2266 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.065 mmol/L | Standard Deviation 0.173 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.076 mmol/L | Standard Deviation 0.1553 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.451 mmol/L | Standard Deviation 0.9158 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -1.469 mmol/L | Standard Deviation 3.8476 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -1.423 mmol/L | Standard Deviation 3.7638 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 8, n=45,32,32,32,26,30,31,28,32,30 | 0.053 mmol/L | Standard Deviation 0.4543 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.029 mmol/L | Standard Deviation 0.1303 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 16, n=50,34,33,34,28,29,32,34,35,33 | 0.025 mmol/L | Standard Deviation 0.2319 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 12, n=50,34,33,34,28,29,32,34,35,33 | 0.011 mmol/L | Standard Deviation 0.2481 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 12, n=45,33,32,32,28,30,31,28,32,32 | 0.156 mmol/L | Standard Deviation 0.4614 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 5, n=41,29,31,29,26,28,29,27,32,29 | 0.026 mmol/L | Standard Deviation 0.5064 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -1.494 mmol/L | Standard Deviation 3.8212 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.447 mmol/L | Standard Deviation 0.8464 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 8, n=50,34,33,34,28,29,32,34,35,31 | -0.004 mmol/L | Standard Deviation 0.2359 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -1.539 mmol/L | Standard Deviation 3.9093 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 16, n=46,33,32,32,28,30,31,28,32,32 | 0.059 mmol/L | Standard Deviation 0.575 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.338 mmol/L | Standard Deviation 0.9449 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.426 mmol/L | Standard Deviation 1.7338 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.183 mmol/L | Standard Deviation 0.8011 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 5, n=41,29,31,29,26,28,29,27,32,29 | -0.106 mmol/L | Standard Deviation 0.4576 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.407 mmol/L | Standard Deviation 0.6393 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 16, n=50,34,33,34,28,29,32,34,35,33 | 0.012 mmol/L | Standard Deviation 0.2065 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 8, n=45,32,32,32,26,30,31,28,32,30 | -0.087 mmol/L | Standard Deviation 0.4336 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 12, n=50,34,33,34,28,29,32,34,35,33 | -0.030 mmol/L | Standard Deviation 0.1796 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 12, n=45,33,32,32,28,30,31,28,32,32 | -0.061 mmol/L | Standard Deviation 0.379 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 8, n=50,34,33,34,28,29,32,34,35,31 | 0.055 mmol/L | Standard Deviation 0.1843 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 16, n=46,33,32,32,28,30,31,28,32,32 | -0.088 mmol/L | Standard Deviation 0.5125 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 5, n=48,33,32,33,27,28,32,34,35,29 | -0.001 mmol/L | Standard Deviation 0.1568 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.047 mmol/L | Standard Deviation 0.1765 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.362 mmol/L | Standard Deviation 1.588 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.054 mmol/L | Standard Deviation 0.1746 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.175 mmol/L | Standard Deviation 1.6289 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.033 mmol/L | Standard Deviation 0.1595 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.033 mmol/L | Standard Deviation 0.1445 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.134 mmol/L | Standard Deviation 0.662 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.725 mmol/L | Standard Deviation 1.3749 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.217 mmol/L | Standard Deviation 0.7376 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.048 mmol/L | Standard Deviation 0.193 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 8, n=50,34,33,34,28,29,32,34,35,31 | 0.175 mmol/L | Standard Deviation 0.8591 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.028 mmol/L | Standard Deviation 1.1012 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 5, n=41,29,31,29,26,28,29,27,32,29 | -0.091 mmol/L | Standard Deviation 0.491 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 12, n=45,33,32,32,28,30,31,28,32,32 | 0.010 mmol/L | Standard Deviation 0.4771 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 16, n=50,34,34,34,28,30,32,34,35,33 | 0.018 mmol/L | Standard Deviation 0.5532 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 12, n=50,34,33,34,28,29,32,34,35,33 | 0.123 mmol/L | Standard Deviation 0.8347 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 8, n=45,32,32,32,26,30,31,28,32,30 | 0.054 mmol/L | Standard Deviation 0.5581 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.245 mmol/L | Standard Deviation 0.5284 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 12, n=50,34,34,34,28,30,32,34,35,33 | -0.045 mmol/L | Standard Deviation 0.1411 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 16, n=50,34,33,34,28,29,32,34,35,33 | 0.094 mmol/L | Standard Deviation 0.8399 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.184 mmol/L | Standard Deviation 0.5912 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 5, n=45,31,34,31,27,29,31,34,35,30 | -0.053 mmol/L | Standard Deviation 0.1129 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 12, n=50,34,34,34,28,30,32,34,35,33 | 0.070 mmol/L | Standard Deviation 0.8288 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 12, n=50,34,34,34,28,30,32,34,35,33 | 0.015 mmol/L | Standard Deviation 0.5786 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | TG, Week 16, n=50,34,34,34,28,30,32,34,35,33 | -0.114 mmol/L | Standard Deviation 1.1446 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | FFA, Week 5, n=48,33,32,33,27,28,32,34,35,29 | 0.006 mmol/L | Standard Deviation 0.2237 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | LDL-C, Week 16, n=46,33,32,32,28,30,31,28,32,32 | 0.054 mmol/L | Standard Deviation 0.4475 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | Total CL, Week 8, n=50,33,34,34,27,30,32,34,35,31 | 0.060 mmol/L | Standard Deviation 0.6296 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16 | HDL-C, Week 8, n=50,33,34,34,27,30,32,34,35,31 | -0.016 mmol/L | Standard Deviation 0.1567 |
Secondary
Change From Baseline in Waist Circumference at Week 16
The Baseline value is the last non-missing value before the start of treatment. Change from Baseline in waist circumference was calculated as the value at Week 16 minus the value at Baseline. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Time frame: Baseline and Week 16
Population: ITT Population. Only participants with a value at Baseline and at Week 16 were analyzed.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Waist Circumference at Week 16 | -0.51 Centimeters | Standard Deviation 3.847 |
| Exenatide BID | Change From Baseline in Waist Circumference at Week 16 | -3.53 Centimeters | Standard Deviation 8.532 |
| Albiglutide 4 mg Weekly | Change From Baseline in Waist Circumference at Week 16 | -1.50 Centimeters | Standard Deviation 3.902 |
| Albiglutide 15 mg Weekly | Change From Baseline in Waist Circumference at Week 16 | -3.16 Centimeters | Standard Deviation 6.901 |
| Albiglutide 30 mg Weekly | Change From Baseline in Waist Circumference at Week 16 | -1.14 Centimeters | Standard Deviation 3.856 |
| Albiglutide 15 mg Bi-weekly | Change From Baseline in Waist Circumference at Week 16 | -1.83 Centimeters | Standard Deviation 3.392 |
| Albiglutide 30 mg Bi-weekly | Change From Baseline in Waist Circumference at Week 16 | -0.47 Centimeters | Standard Deviation 3.589 |
| Albiglutide 50 mg Bi-weekly | Change From Baseline in Waist Circumference at Week 16 | -2.00 Centimeters | Standard Deviation 5.454 |
| Albiglutide 50 mg Every 4 Weeks | Change From Baseline in Waist Circumference at Week 16 | -0.88 Centimeters | Standard Deviation 5.146 |
| Albiglutide 100 mg Every 4 Weeks | Change From Baseline in Waist Circumference at Week 16 | -0.77 Centimeters | Standard Deviation 4.161 |
Secondary
Mean Absorption Rate of Albiglutide
Absorption rate is defined as the rate at which albiglutide enters the blood circulation. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 4, 5, 7, 8, 9, 12, 15) and on the day of the clinic visit at Weeks 16, 17, 18, 20, 23, and 27. The Week 5, 8, and 12 post-dose (PK sampling was performed within 6 days of drug administration.
Time frame: Weeks 0, 4, 5, 7, 8, 9, 12, 15, 16, 17 18, 20, 23, and 27
Population: PK Analysis Population
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Placebo | Mean Absorption Rate of Albiglutide | 0.0193 hour^-1 |
Secondary
Mean Clearance of Albiglutide
Clearance is defined as the volume of plasma cleared of albiglutide per unit time. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 4, 5, 7, 8, 9, 12, 15) and on the day of the clinic visit at Weeks 16, 17, 18, 20, 23, and 27. The Week 5, 8, and 12 post-dose pharmacokinetic (PK) sampling was performed within 6 days of drug administration.
Time frame: Weeks 0, 4, 5, 7, 8, 9, 12, 15, 16, 17 18, 20, 23, and 27
Population: PK Analysis Population: all participants for whom a PK sample was obtained and analyzed
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Placebo | Mean Clearance of Albiglutide | 94.2 milliliters per hour |
Secondary
Mean Half-maximal Effective Concentration (EC50) of Albiglutide for HbA1c and FPG
EC50 is defined as the concentration of albiglutide that give a half-maximal HbA1c and FPG response. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 4, 5, 7, 8, 9, 12, 15) and on the day of the clinic visit at Weeks 16, 17, 18, 20, 23, and 27. The Week 5, 8, and 12 post-dose (PK sampling was performed within 6 days of drug administration. EC50 estimates used PK data as well as HbA1c and FPG efficacy data. EC50 was estimated from an inhibitory Emax (maximal possible effect of albiglutide) model.
Time frame: Weeks 0, 4, 5, 7, 8, 9, 12, 15, 16, 17 18, 20, 23, and 27
Population: PK/PD Analysis Population: all participants in the PK Analysis Population with sufficient dosing history for inclusion in the PK/PD analysis
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Placebo | Mean Half-maximal Effective Concentration (EC50) of Albiglutide for HbA1c and FPG | HbA1c, Treatment-naïve group | 1140 nanograms per milliliter |
| Placebo | Mean Half-maximal Effective Concentration (EC50) of Albiglutide for HbA1c and FPG | HbA1c, Prior monotherapy group | 1230 nanograms per milliliter |
| Placebo | Mean Half-maximal Effective Concentration (EC50) of Albiglutide for HbA1c and FPG | FPG | 1970 nanograms per milliliter |
Secondary
Mean Volume of Distribution of Albiglutide
Volume of distribution is defined as the apparent volume in which albiglutide is distributed. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 4, 5, 7, 8, 9, 12, 15) and on the day of the clinic visit at Weeks 16, 17, 18, 20, 23, and 27. The Week 5, 8, and 12 post-dose (PK sampling was performed within 6 days of drug administration.
Time frame: Weeks 0, 4, 5, 7, 8, 9, 12, 15, 16, 17 18, 20, 23, and 27
Population: PK Analysis Population
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Placebo | Mean Volume of Distribution of Albiglutide | 16400 Liters |
Secondary
Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16
The number of participants who achieved target values for HbA1c (i.e., HbA1c \<6.5% and \>=6.5% to \<7%) were assessed. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Time frame: Weeks (W) 4, 5, 7, 8, 9, 12, 15, and 16
Population: ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed for different parameters at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W8: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 1 Participants |
| Placebo | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W7: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 9 Participants |
| Placebo | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W16: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 2 Participants |
| Placebo | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W15:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 8 Participants |
| Placebo | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W15: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 3 Participants |
| Placebo | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W12:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 7 Participants |
| Placebo | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W12: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 3 Participants |
| Placebo | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W9: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 9 Participants |
| Placebo | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W9: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 3 Participants |
| Placebo | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W7: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 1 Participants |
| Placebo | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W16:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 8 Participants |
| Placebo | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W5: >=6.5% to <7%, n=49,34,34,34,29,30,32,34,35,31 | 4 Participants |
| Placebo | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W5: <6.5%, n=49,34,34,34,29,30,32,34,35,31 | 2 Participants |
| Placebo | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W4: >=6.5% to <7%, n=47,34,33,34,28,29,31,34,34,30 | 8 Participants |
| Placebo | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W4: <6.5%, n=47,34,33,34,28,29,31,34,34,30 | 1 Participants |
| Placebo | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W8: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 10 Participants |
| Exenatide BID | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W8: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 7 Participants |
| Exenatide BID | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W7: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 1 Participants |
| Exenatide BID | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W7: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 9 Participants |
| Exenatide BID | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W8: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 2 Participants |
| Exenatide BID | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W5: >=6.5% to <7%, n=49,34,34,34,29,30,32,34,35,31 | 7 Participants |
| Exenatide BID | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W4: <6.5%, n=47,34,33,34,28,29,31,34,34,30 | 0 Participants |
| Exenatide BID | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W4: >=6.5% to <7%, n=47,34,33,34,28,29,31,34,34,30 | 5 Participants |
| Exenatide BID | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W5: <6.5%, n=49,34,34,34,29,30,32,34,35,31 | 0 Participants |
| Exenatide BID | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W9: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 2 Participants |
| Exenatide BID | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W9: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 9 Participants |
| Exenatide BID | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W12: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 3 Participants |
| Exenatide BID | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W12:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 8 Participants |
| Exenatide BID | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W15: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 4 Participants |
| Exenatide BID | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W15:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 6 Participants |
| Exenatide BID | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W16: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 4 Participants |
| Exenatide BID | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W16:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 8 Participants |
| Albiglutide 4 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W5: >=6.5% to <7%, n=49,34,34,34,29,30,32,34,35,31 | 5 Participants |
| Albiglutide 4 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W4: <6.5%, n=47,34,33,34,28,29,31,34,34,30 | 0 Participants |
| Albiglutide 4 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W16:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 3 Participants |
| Albiglutide 4 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W16: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 3 Participants |
| Albiglutide 4 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W8: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 1 Participants |
| Albiglutide 4 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W15: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 2 Participants |
| Albiglutide 4 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W12: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 2 Participants |
| Albiglutide 4 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W12:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 4 Participants |
| Albiglutide 4 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W9: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 5 Participants |
| Albiglutide 4 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W8: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 6 Participants |
| Albiglutide 4 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W9: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 2 Participants |
| Albiglutide 4 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W7: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 1 Participants |
| Albiglutide 4 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W15:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 5 Participants |
| Albiglutide 4 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W5: <6.5%, n=49,34,34,34,29,30,32,34,35,31 | 1 Participants |
| Albiglutide 4 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W7: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 4 Participants |
| Albiglutide 4 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W4: >=6.5% to <7%, n=47,34,33,34,28,29,31,34,34,30 | 5 Participants |
| Albiglutide 15 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W8: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 4 Participants |
| Albiglutide 15 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W12: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 5 Participants |
| Albiglutide 15 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W7: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 4 Participants |
| Albiglutide 15 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W8: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 8 Participants |
| Albiglutide 15 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W4: <6.5%, n=47,34,33,34,28,29,31,34,34,30 | 1 Participants |
| Albiglutide 15 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W16: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 4 Participants |
| Albiglutide 15 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W4: >=6.5% to <7%, n=47,34,33,34,28,29,31,34,34,30 | 8 Participants |
| Albiglutide 15 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W5: >=6.5% to <7%, n=49,34,34,34,29,30,32,34,35,31 | 7 Participants |
| Albiglutide 15 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W7: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 4 Participants |
| Albiglutide 15 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W15:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 8 Participants |
| Albiglutide 15 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W5: <6.5%, n=49,34,34,34,29,30,32,34,35,31 | 2 Participants |
| Albiglutide 15 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W15: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 4 Participants |
| Albiglutide 15 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W9: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 6 Participants |
| Albiglutide 15 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W12:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 8 Participants |
| Albiglutide 15 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W16:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 8 Participants |
| Albiglutide 15 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W9: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 7 Participants |
| Albiglutide 30 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W16:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 5 Participants |
| Albiglutide 30 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W12: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 11 Participants |
| Albiglutide 30 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W5: <6.5%, n=49,34,34,34,29,30,32,34,35,31 | 4 Participants |
| Albiglutide 30 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W12:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 5 Participants |
| Albiglutide 30 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W9: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 8 Participants |
| Albiglutide 30 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W7: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 5 Participants |
| Albiglutide 30 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W16: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 10 Participants |
| Albiglutide 30 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W8: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 6 Participants |
| Albiglutide 30 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W4: <6.5%, n=47,34,33,34,28,29,31,34,34,30 | 4 Participants |
| Albiglutide 30 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W7: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 8 Participants |
| Albiglutide 30 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W5: >=6.5% to <7%, n=49,34,34,34,29,30,32,34,35,31 | 8 Participants |
| Albiglutide 30 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W15:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 7 Participants |
| Albiglutide 30 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W8: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 8 Participants |
| Albiglutide 30 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W4: >=6.5% to <7%, n=47,34,33,34,28,29,31,34,34,30 | 8 Participants |
| Albiglutide 30 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W15: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 8 Participants |
| Albiglutide 30 mg Weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W9: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 5 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W7: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 9 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W15:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 7 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W12:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 7 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W9: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 10 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W5: <6.5%, n=49,34,34,34,29,30,32,34,35,31 | 1 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W8: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 9 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W15: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 4 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W12: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 3 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W16:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 3 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W4: <6.5%, n=47,34,33,34,28,29,31,34,34,30 | 0 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W9: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 1 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W16: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 5 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W7: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 1 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W8: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 1 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W4: >=6.5% to <7%, n=47,34,33,34,28,29,31,34,34,30 | 6 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W5: >=6.5% to <7%, n=49,34,34,34,29,30,32,34,35,31 | 5 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W9: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 11 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W8: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 4 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W7: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 3 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W8: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 12 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W4: <6.5%, n=47,34,33,34,28,29,31,34,34,30 | 0 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W4: >=6.5% to <7%, n=47,34,33,34,28,29,31,34,34,30 | 8 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W5: <6.5%, n=49,34,34,34,29,30,32,34,35,31 | 1 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W9: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 3 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W12: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 3 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W5: >=6.5% to <7%, n=49,34,34,34,29,30,32,34,35,31 | 9 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W12:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 13 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W16:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 12 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W15: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 6 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W15:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 8 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W16: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 4 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W7: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 11 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W8: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 7 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W4: <6.5%, n=47,34,33,34,28,29,31,34,34,30 | 3 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W12: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 8 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W16:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 8 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W5: <6.5%, n=49,34,34,34,29,30,32,34,35,31 | 2 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W4: >=6.5% to <7%, n=47,34,33,34,28,29,31,34,34,30 | 5 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W15:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 9 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W9: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 7 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W7: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 6 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W7: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 9 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W5: >=6.5% to <7%, n=49,34,34,34,29,30,32,34,35,31 | 11 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W8: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 10 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W12:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 11 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W16: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 10 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W9: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 10 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W15: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 10 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W7: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 2 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W5: >=6.5% to <7%, n=49,34,34,34,29,30,32,34,35,31 | 7 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W9: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 2 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W12:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 9 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W7: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 8 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W8: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 4 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W15: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 3 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W5: <6.5%, n=49,34,34,34,29,30,32,34,35,31 | 1 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W4: >=6.5% to <7%, n=47,34,33,34,28,29,31,34,34,30 | 6 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W15:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 8 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W16:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 5 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W4: <6.5%, n=47,34,33,34,28,29,31,34,34,30 | 1 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W16: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 3 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W8: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 2 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W12: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 2 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W9: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 9 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W15: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 9 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W16: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 8 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W7: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 5 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W7: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 8 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W5: <6.5%, n=49,34,34,34,29,30,32,34,35,31 | 4 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W8: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 11 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W9: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 9 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W8: <6.5%, n=50,34,34,34,29,30,32,34,35,32 | 5 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W5: >=6.5% to <7%, n=49,34,34,34,29,30,32,34,35,31 | 12 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W4: >=6.5% to <7%, n=47,34,33,34,28,29,31,34,34,30 | 6 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W9: >=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,32 | 8 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W15:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 7 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W16:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 8 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W12: <6.5%, n=50,34,34,34,29,30,32,34,35,33 | 7 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W4: <6.5%, n=47,34,33,34,28,29,31,34,34,30 | 3 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants Who Achieved Target Values for HbA1c <6.5% and >=6.5% to <7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16 | W12:>=6.5% to <7%, n=50,34,34,34,29,30,32,34,35,33 | 8 Participants |
Secondary
Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16
The HCFQ questionnaire is used to record how often participants have felt hungry or craved food, and how full participants felt after finishing meals, on average, in the past week. Participants answered the following seven questions with the response that best described their feelings of hunger, craving, and fullness: Q1, In the past week I was hungry; Q2, In the past week I thought about food; Q3, In the past week I wanted to eat; Q4, In the past week I ate more than I should have; Q5, In the past week, I craved specific food; Q6, In the past week when finished meals I felt full; Q7, In the past week when finished meals I felt satisfied.
Time frame: Week 16
Population: Safety Population. Only those participants available at the specified time point were analyzed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Sometimes | 26 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Slightly hungry | 3 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Dissatisfied | 0 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Much too full | 0 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Rarely | 4 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Yes, probably | 15 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Sometimes | 28 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Always | 1 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Often | 2 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Probably not | 7 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Comfortably full | 26 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Never | 1 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: I don't know | 10 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Very full | 10 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Often | 5 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Sometimes | 28 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Extremely satisfied | 3 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Always | 1 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Very hungry | 0 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Often | 7 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Satisfied | 27 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Yes, definitely | 4 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Often | 4 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Extremely dissatisfied | 0 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Neither satisfied nor dissatisfied | 9 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Never | 1 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Definitely not | 3 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Sometimes | 19 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Never | 1 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Always | 3 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Always | 1 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Rarely | 16 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Rarely | 5 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Never | 0 Participants |
| Placebo | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Rarely | 3 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Rarely | 5 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Always | 1 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Neither satisfied nor dissatisfied | 3 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Always | 0 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Sometimes | 20 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Dissatisfied | 0 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Definitely not | 4 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Often | 5 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Extremely dissatisfied | 0 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Never | 4 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Often | 2 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Rarely | 4 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Rarely | 8 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Probably not | 12 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Much too full | 0 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Very full | 2 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Sometimes | 19 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Sometimes | 17 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: I don't know | 5 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Comfortably full | 28 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Never | 1 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Always | 1 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Yes, probably | 8 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Slightly hungry | 0 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Yes, definitely | 1 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Very hungry | 0 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Rarely | 7 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Sometimes | 15 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Often | 5 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Never | 0 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Extremely satisfied | 0 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Often | 5 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Satisfied | 27 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Never | 1 Participants |
| Exenatide BID | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Always | 0 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Slightly hungry | 0 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Always | 0 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Never | 3 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Always | 0 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Extremely dissatisfied | 0 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Yes, definitely | 0 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Sometimes | 16 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Often | 4 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Always | 0 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Sometimes | 14 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Very hungry | 0 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Always | 0 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Often | 2 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Rarely | 1 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Never | 1 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Rarely | 11 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Never | 0 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Often | 2 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Very full | 3 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Definitely not | 1 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: I don't know | 2 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Rarely | 3 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Often | 2 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Sometimes | 15 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Satisfied | 17 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Comfortably full | 18 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Rarely | 5 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Extremely satisfied | 1 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Neither satisfied nor dissatisfied | 3 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Yes, probably | 8 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Dissatisfied | 0 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Much too full | 0 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Never | 0 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Probably not | 10 Participants |
| Albiglutide 4 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Sometimes | 5 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Sometimes | 13 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Never | 0 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Often | 7 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Always | 0 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Rarely | 4 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Often | 4 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Definitely not | 4 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Never | 4 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Probably not | 9 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Much too full | 1 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: I don't know | 1 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Very full | 5 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Yes, probably | 9 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Comfortably full | 17 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Always | 0 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Slightly hungry | 2 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Yes, definitely | 2 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Very hungry | 0 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Never | 0 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Extremely satisfied | 1 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Rarely | 2 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Satisfied | 17 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Sometimes | 13 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Neither satisfied nor dissatisfied | 5 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Sometimes | 18 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Dissatisfied | 2 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Often | 4 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Extremely dissatisfied | 0 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Always | 1 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Always | 0 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Never | 0 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Often | 7 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Sometimes | 14 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Rarely | 5 Participants |
| Albiglutide 15 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Rarely | 4 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Neither satisfied nor dissatisfied | 1 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Always | 0 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Always | 0 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Sometimes | 13 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Satisfied | 19 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Rarely | 1 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Never | 0 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Often | 7 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Extremely satisfied | 1 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Never | 0 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Very hungry | 0 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Sometimes | 11 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Often | 6 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Slightly hungry | 1 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Yes, definitely | 2 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Comfortably full | 18 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Yes, probably | 9 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Rarely | 4 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Always | 2 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Very full | 3 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: I don't know | 1 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Rarely | 2 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Sometimes | 14 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Definitely not | 3 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Never | 0 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Much too full | 0 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Probably not | 7 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Never | 0 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Extremely dissatisfied | 0 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Often | 7 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Always | 1 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Rarely | 5 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Often | 1 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Dissatisfied | 1 Participants |
| Albiglutide 30 mg Weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Sometimes | 14 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Sometimes | 10 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Often | 1 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Sometimes | 7 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Rarely | 8 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Never | 3 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Much too full | 0 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Very full | 4 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Comfortably full | 13 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Slightly hungry | 2 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Very hungry | 0 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Extremely satisfied | 0 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Satisfied | 15 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Neither satisfied nor dissatisfied | 3 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Dissatisfied | 1 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Extremely dissatisfied | 0 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Always | 2 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Often | 3 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Sometimes | 8 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Rarely | 6 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Never | 0 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Always | 1 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Often | 3 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Sometimes | 10 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Rarely | 4 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Never | 1 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Always | 1 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Often | 4 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Rarely | 4 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Never | 0 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Yes, definitely | 2 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Yes, probably | 9 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: I don't know | 2 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Probably not | 4 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Definitely not | 2 Participants |
| Albiglutide 15 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Always | 0 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Slightly hungry | 0 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Rarely | 0 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Comfortably full | 20 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Extremely dissatisfied | 0 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Rarely | 2 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Yes, probably | 12 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Often | 6 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Dissatisfied | 0 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Always | 2 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Often | 4 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Never | 1 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Sometimes | 17 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Yes, definitely | 2 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Probably not | 4 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Never | 0 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Very full | 4 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Neither satisfied nor dissatisfied | 1 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Never | 0 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Never | 1 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Sometimes | 16 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Often | 5 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Rarely | 0 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Always | 2 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Definitely not | 3 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Satisfied | 22 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Much too full | 1 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Often | 6 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Very hungry | 0 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Sometimes | 15 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Rarely | 1 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Sometimes | 15 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Always | 3 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Always | 4 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Extremely satisfied | 2 Participants |
| Albiglutide 30 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: I don't know | 4 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Rarely | 6 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Very hungry | 0 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Never | 2 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Often | 2 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Much too full | 1 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Slightly hungry | 0 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Very full | 2 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Yes, definitely | 2 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Always | 2 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Yes, probably | 5 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Rarely | 4 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Comfortably full | 18 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Sometimes | 9 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Always | 0 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Never | 3 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Often | 3 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Definitely not | 7 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Always | 2 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Extremely dissatisfied | 0 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Always | 3 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Often | 3 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Sometimes | 11 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Dissatisfied | 0 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Sometimes | 9 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Often | 2 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Probably not | 5 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Never | 2 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Neither satisfied nor dissatisfied | 5 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Sometimes | 12 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Never | 3 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Satisfied | 15 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Rarely | 4 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Extremely satisfied | 1 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Rarely | 2 Participants |
| Albiglutide 50 mg Bi-weekly | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: I don't know | 2 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Rarely | 2 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Sometimes | 16 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Sometimes | 20 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Sometimes | 11 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Rarely | 4 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Often | 6 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Always | 2 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Never | 1 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Extremely dissatisfied | 0 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Always | 3 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Dissatisfied | 1 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Often | 6 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Neither satisfied nor dissatisfied | 4 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Satisfied | 23 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Sometimes | 17 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Extremely satisfied | 2 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Often | 5 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Rarely | 4 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Very hungry | 1 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Never | 0 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Slightly hungry | 2 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Yes, definitely | 7 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Comfortably full | 18 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Very full | 7 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Yes, probably | 9 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Much too full | 2 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Always | 0 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: I don't know | 2 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Never | 5 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Probably not | 10 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Rarely | 9 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Always | 3 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Never | 0 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Definitely not | 2 Participants |
| Albiglutide 50 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Often | 6 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Rarely | 1 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Often | 6 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: I don't know | 2 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Extremely satisfied | 1 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Never | 3 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Definitely not | 1 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Sometimes | 11 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Satisfied | 14 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Always | 0 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Neither satisfied nor dissatisfied | 5 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Often | 9 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Sometimes | 12 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Probably not | 4 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Rarely | 8 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Sometimes | 11 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Often | 3 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Dissatisfied | 2 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q5: Sometimes | 8 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Always | 0 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q7: Extremely dissatisfied | 0 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Never | 1 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Rarely | 2 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Always | 2 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Always | 1 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Very full | 2 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Yes, definitely | 3 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Rarely | 2 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q4: Yes, probably | 12 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Comfortably full | 17 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Slightly hungry | 2 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Much too full | 1 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q1: Never | 1 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q3: Never | 1 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q2: Often | 6 Participants |
| Albiglutide 100 mg Every 4 Weeks | Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16 | Q6: Very hungry | 0 Participants |
Secondary
Percent Change From Baseline in Body Weight at Week 16
The Baseline value is the last non-missing value before the start of treatment. Change from Baseline in body weight was calculated as the value at Week 16 minus the value at Baseline. Percent change from Baseline was calculated as the (\[value at Week 16 minus the Baseline value\] divided by the Baseline value) multiplied by 100. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Time frame: Baseline and Week 16
Population: ITT Population. Only participants with a value at Baseline and at Week 16 were analyzed.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Percent Change From Baseline in Body Weight at Week 16 | -0.72 Percent change | Standard Deviation 3.403 |
| Exenatide BID | Percent Change From Baseline in Body Weight at Week 16 | -2.53 Percent change | Standard Deviation 4.307 |
| Albiglutide 4 mg Weekly | Percent Change From Baseline in Body Weight at Week 16 | -0.94 Percent change | Standard Deviation 1.838 |
| Albiglutide 15 mg Weekly | Percent Change From Baseline in Body Weight at Week 16 | -1.04 Percent change | Standard Deviation 3.261 |
| Albiglutide 30 mg Weekly | Percent Change From Baseline in Body Weight at Week 16 | -1.59 Percent change | Standard Deviation 2.663 |
| Albiglutide 15 mg Bi-weekly | Percent Change From Baseline in Body Weight at Week 16 | -1.97 Percent change | Standard Deviation 2.908 |
| Albiglutide 30 mg Bi-weekly | Percent Change From Baseline in Body Weight at Week 16 | -1.69 Percent change | Standard Deviation 2.773 |
| Albiglutide 50 mg Bi-weekly | Percent Change From Baseline in Body Weight at Week 16 | -1.32 Percent change | Standard Deviation 3.16 |
| Albiglutide 50 mg Every 4 Weeks | Percent Change From Baseline in Body Weight at Week 16 | -1.37 Percent change | Standard Deviation 3.571 |
| Albiglutide 100 mg Every 4 Weeks | Percent Change From Baseline in Body Weight at Week 16 | -1.89 Percent change | Standard Deviation 3.19 |